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ABSTRACT 
 
Chronic obstructive pulmonary disease (COPD) is a complex syndrome and an 
important public health challenge. Although defined as a chronic inflammatory 
respiratory disease, COPD is heterogeneous, being characterized by a number 
of systemic consequences and co-morbidities, which contribute to disease 
severity. Specifically, nutritional disorders (i.e. malnutrition) and nutrition-
related conditions (i.e. muscle dysfunction) are highly prevalent extra 
pulmonary manifestations of COPD, associated with important consequences 
for risk assessment stratification and management of the disease.   
General aim of this thesis was to investigate the occurrence of alterations of 
body composition and its relationship with muscle strength. More specifically, 
five studies on COPD patients had been carried out in order to systematically 
review the use of bioelectrical impedance analysis (BIA) for the assessment of 
body composition; to evaluate the prevalence of malnutrition and sarcopenia 
and their relationship with functional parameters; to compare BIA variables 
between COPD patients and controls and to study the association of muscle 
strength with body composition estimates and BIA variables. As a final point, 
this thesis aimed to explore the amount of visceral adipose tissue located in the 
abdominal region using dual-energy x-ray absorptiometry and to determine its 
relation with respiratory parameters and other indices of body composition. 
In conclusion, this thesis provides a detailed overview of the assessment of 
nutritional status and body composition in COPD patients, especially in relation 
with respiratory function and muscle strength, bringing to light the need for 
prevention strategies and suggesting possible tools for the implementation of 
personalized approaches for COPD patients. 
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 INTRODUCTION 
 
 
 
 
 
 
 
 
SUMMARY: 1. COPD: general introduction – 1.1 Background and definition 
– 1.2 Burden of the disease – 1.3 Risk factors – 1.4 Diagnosis and Assessment 
– 2. Nutritional status in COPD   – 2.1 Malnutrition – 2.2 Nutritional phenotypes 
in COPD – 3. Body composition in COPD – 3.1 Body mass index (BMI) – 3.2 
Fat-free mass (FFM) – 3.3 Appendicular skeletal muscle mass (ASM) – 3.4 
Bone mineral density (BMD) – 3.5 Body fat and body fat distribution – 4. 
Muscle strength in COPD – 5. Tables and figures – 6. References.  
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1. COPD: general introduction 
1.1 Background and definition 
Chronic obstructive pulmonary disease (COPD) is an important public health 
challenge that is both preventable and treatable. COPD represents a major cause 
of morbidity and mortality worldwide. It is currently the fourth leading cause of 
death in the world. Many people suffer from COPD and die for it or for disease-
related complications (1).  
According to the current definition, COPD is a common, preventable and 
treatable disease, characterized by persistent respiratory symptoms and airflow 
limitation that is due to airway and/or alveolar abnormalities usually caused by 
significant exposure to noxious particles or gases (2). 
1.2 Burden of the disease 
Prevalence 
The prevalence of COPD is directly related to the prevalence of tobacco 
smoking, although in many countries (especially developing countries), 
outdoor, occupational and indoor air pollution are major COPD risk factors (3). 
A systematic review and meta-analysis of studies carried out in 28 countries 
between 1990 and 2004 (4), provides evidence that the prevalence of COPD in 
adults aged ≥40 years is around 9–10%, being higher in smokers and ex-
smokers compared to non-smokers, in those older than 40 years compared to 
those younger than 40, and in men compared to women. 
Mortality 
COPD is one of the most important causes of death in the world. According to 
world health organization (WHO), COPD, which was the sixth leading cause of 
death in 1990, will become the third by 2020, probably reflecting the increase 
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in smoking habits, the reduction of mortality from other causes (e.g. infectious 
diseases), as well as aging of the world population (5). However, data must be 
interpreted with caution due to the under-recognition and under-diagnosis of 
COPD, which reduces the accuracy of mortality data (6, 7). 
1.3 Risk factors 
COPD is a chronic inflammatory process in the lower airways and the lung 
parenchyma that results from a complex interaction between environment and 
genes. The most important environmental risk factor for COPD is cigarette 
smoking (8), but other types of tobacco (e.g. piper, cigar, water pipe) (9, 10) and 
marijuana (11) are also risk factors for COPD. Passive exposure to cigarette 
smoke may also contribute to COPD risk (12). Other modifiable documented 
factors may increase the risk of COPD, i.e. occupational airborne exposure 
(occupational dust, chemicals and vapors derived from mining, agriculture, and 
textile, paper, wood, chemical, and food processing), outdoor and indoor 
pollution, socioeconomic status and early life environmental factors (e.g. 
smoking mothers, frequent respiratory infections and asthma in childhood). 
Besides environmental modifiable risk factors, genes may also play a role 
in the development of COPD.  The genetic risk factor that is best documented 
is hereditary α1-antitrypsin deficiency (13), a protease inhibitor belonging to 
the serpin superfamily, which protects tissues from enzymes of inflammatory 
cells, especially neutrophil elastase. However, homozygous α1-antitrypsin 
deficiency is very uncommon, being found in fewer than five people per 10000. 
1.4 Diagnosis and Assessment 
Diagnosis  
In presence of symptoms such as dyspnoea, chronic cough, chronic sputum 
production, recurrent lower respiratory tract infections and/or history of risk 
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factors, which can increase the probability of the disease, diagnosis of COPD 
should be considered. Diagnostic criterion is officially based on spirometry, the 
most reproducible and objective method for the assessment of airflow 
limitation. It measures the volume of air exhaled from the point of maximal 
inspiration (forced vital capacity, FVC) and the volume of air exhaled during 
the first second of this procedure (forced expiratory volume in 1 second, FEV1). 
A reduction of the ratio between FEV1 and FVC   (<0,70) confirms the diagnosis 
of COPD (1). 
Disease severity 
Specific spirometric cut-points are currently used in order to classify the 
severity of airflow limitation in COPD (table 1). However, it has been recently 
reported only a week correlation between spirometrc data, symptoms and 
impairment of patient’s health status (1, 14). Hence, more extended 
symptomatic assessment is required. The two measures of symptoms most 
widely used are the Modified British Medical Research Council (mMRC) 
questionnaire and the COPD Assessment Test (CAT). The former is a simple 
measurement of breathless, which ranges from 0-4, being related well with 
health status (15) and mortality risk (16). The latter is an 8-items unidimentional 
measure of health status impairment in COPD (17), whose score ranges from 0-
40 and correlates very well with health status, depression and mortality (18). 
In this contest, a new “ABCD” assessment tool based on dyspnoea and 
symptoms (mMRC and CAT), in combination with spirometric data and history 
of exacerbations, has been proposed in the latest 2017 GOLD document (1). 
Assessment of comorbidities 
Although the most important symptoms of COPD are breathlessness on exertion 
and chronic cough, patients with COPD often suffer from other diseases (i.e. 
hyperglycemia, atherosclerosis, hypertension, dyslipidemia, osteoporosis, 
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obesity, sarcopenia, renal impairment and anxiety), linked to the same risk 
factors, i.e. smoking, ageing and inactivity. 
Airflow limitation affects gas exchange and cardiac function (19). At the 
same time, the chronic low-grade inflammation may contribute to weight loss, 
skeletal muscle wasting and cachexia (20-22) and may cause or worsen 
comorbidities such as ischaemic heart disease, heart failure, osteoporosis, 
anaemia, hyperglycemia and metabolic syndrome (23). 
 Comorbidities were found to be present in the COPD population with 
frequencies that ranged from 5–54%, with hyperglycemia, atherosclerosis, 
hypertension, dyslipidemia, and osteoporosis among the five most prevalent 
comorbidities (24). 
Phenotyping 
COPD is a syndrome with many phenotypes that influence the clinical 
progression of the disease. In general terms, a phenotype is an observable 
characteristic of an organism, which is determined by its genotype and 
modulated by its environment (25). A clinical COPD phenotype has been 
defined as “A single or combination of disease attributes that describe 
differences between individuals with COPD as they relate to clinically 
meaningful outcomes (e.g. symptoms, exacerbations, response to therapy or 
death)” (26). 
Although a COPD phenotype describes differences between individuals 
with COPD, clinical phenotyping may be problematical for several reasons. 
First, some clinical phenotypes may change due to the natural course of the 
disease or, in response to the therapy. Furthermore, a certain patient can have 
more than one clinical phenotype. Finally, two prevalent respiratory diseases 
can coexist (e.g. COPD and obstructive sleep apnoea or asthma) (2). 
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Only few clinical COPD phenotypes have been validated. They include α1-
antitrypsin deficiency, frequent (two or more per year) exacerbations, chronic 
bronchitis and emphysema (2). Furthermore, besides the classic description of 
the clinical phenotypes, several nutritional phenotypes have been recently 
proposed in COPD by Schols et al., indicating the need for a multidimensional 
approach (27). 
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2. Nutritional status in COPD   
Although defined as a chronic inflammatory respiratory disease, COPD is 
heterogeneous, with respect to pulmonary events, systemic consequences (e.g. 
weight loss and muscle weakness) and co-morbidity (e.g. osteoporosis, diabetes 
and cardiovascular disease), which contribute to disease severity (28). 
Nutritional disorders (i.e. malnutrition) and nutrition-related conditions (i.e. 
sarcopenia) are highly prevalent extra pulmonary manifestations of COPD, 
associated with important consequences for health risk assessment, 
stratification and management of the disease. 
In this perspective, nutritional assessment is essential and highly 
recommended in COPD management (2), in order to develop targeted and 
personalized nutritional interventions.  
2.1 Malnutrition 
Definition 
According to the latest European Society of Clinical Nutrition and Metabolism 
(ESPEN) guidelines, malnutrition can be defined as “a state resulting from lack 
of intake or uptake of nutrition that leads to altered body composition and body 
cell mass leading to diminished physical and mental function and impaired 
clinical outcome from disease” (29).  
Malnutrition is a common and serious problem and one of the most relevant 
systemic manifestation of COPD. Loss of body weight occurs when energy 
expenditure exceeds energy intake. In COPD, eating is an activity that can 
increase dyspnoea in patients with severe disease (30). Ageing is also a 
contributing factor to reduced energy intake in COPD, probably due to its 
typical symptoms, as loss of taste, poor dentition, dysphagia, poor chewing and 
swallowing ability; social problems as living or eating alone; and inability to 
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self-feed (31). Anorexia is, however, not the only determinant of a reduced 
energy intake in underweight COPD patients (32, 33). In fact, while the normal 
response to semi-starvation is a reduced metabolic rate and depressed whole-
body protein turnover, COPD patients may show increased resting energy 
expenditure and whole-body protein turnover (34). Furthermore, in addition to 
an increased cost of ventilation due to abnormal pulmonary mechanics, a higher 
ATP cost of muscular contraction, due to the muscle fiber shift from type I 
(oxidative) to type II (glycolytic), may contribute to the elevated daily energy 
expenditure in some COPD patients (35). 
Malnutrition is an important determinant of other the extra-pulmonary 
effects, including skeletal muscle dysfunction, osteoporosis, cardiovascular 
disease and poor prognosis (36, 37). In addition, it contributes to a further 
phenotyping of these patients. 
Diagnosis 
Several criteria can be used to capture the state of malnutrition, including weight 
loss, low BMI, anthropometry (mid-arm circumference, calf circumference, 
triceps skinfolds thickness), body composition (fat-free mass), loss of appetite, 
reduced food intake and biochemical indicators (albumin, prealbumin, total 
lymphocyte count) (38-40). 
Actually, according to the latest ESPEN consensus statement on 
malnutrition (41), three variables were chosen to most accurately reflect 
malnutrition, specifically weight loss, reduced BMI and reduced FFMI. With 
this perspective, Schols et al. (27) established a nutritional risk diagram for 
COPD patients, based on prospective assessment of body weight (change) and 
body composition. 
In addition, several nutritional screening tools have been developed for 
rating the nutritional status of elderly (table 2), such as Malnutrition Universal 
Screening Tool (MUST), Nutritional Risk Screening (NRS), Mini Nutritional 
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Assessment (MNA) and Subjective Global Assessment (SGA). Those tools can 
be used with the purpose of identifying patients at nutritional risk, in order to 
detect those that will need further nutritional assessment and that will need 
nutritional therapy.  
MUST 
The MUST is a nutritional screening tool, validated for use in hospitals (42). It 
is based on three criteria, BMI, unintentional weight loss over the previous three 
to six months and significant decrease in food intake associated with acute 
illness for a period of more than five days (43). The final score of the MUST 
was obtained by adding the scores for each of the three parameters evaluated, 
ranking undernutrition risk as low, moderate or high, if the score is 0, 1, or 
higher than or equal to 2, respectively (43). Different screening and nutritional 
evaluation tools have been compared, including MUST, MNA, SGA, SGA and 
NRS in hospital, showing that MUST compared to the other tools reviewed had 
reasonable to excellent validity, as well as being quick and easy to use and it 
also demonstrated excellent reproducibility among different users (42). 
NRS 
The NRS score is the sum of the scores in disease severity, nutritional status, 
and age, and range between 0 and 7. Disease severity of the patients was scored 
based on the diagnosis records at admission. The nutritional status of each 
patient was scored based on the changes in body weight and BMI in the recent 
three months and food intake in the recent 1 week. Furthermore, 1 score was 
assigned to the patients who were more than 70 years old. According to the NRS 
score, the patients are divided in those at nutritional risk (if NRS score≥3) and 
those not at nutritional risk (NRS score<3). Previous studies supported the 
association between exercise capacity and nutritional risk according to NRS in 
severe COPD male patients (44). However, more studies are needed to confirm 
this relationship in COPD. 
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MNA  
The MNA is one of the most widely used ones. It is an easy, low-cost, fast and 
non-invasive tool that has been shown to perform well in elderly living with 
various health conditions (45). The MNA consists of 18 items and evaluates 4 
areas of nutritional status—anthropometric, dietary, global and self-rated status. 
The MNA has a maximum score of 30. A score ≤ 16.5 suggests 
malnourishment; 17–23.5 suggests at risk of malnutrition, and ≥ 24 suggests 
normal (46), suggesting a role of MNA for gaining an insight into the nutritional 
problems in patients with COPD, providing useful indications for treatment 
strategies. However, only a few studies have used the MNA to estimate 
nutritional status of patients with COPD (37, 47-50). According to this 
nutritional screening tool, 14% of patients with COPD were found to be 
malnourished and another 55% at risk of malnutrition (49). A positive 
association of MNA score with lean body mass (49) has been previously 
proposed, as well as a negative association with dyspnoea in 32 ≥ 60-year-old 
patients with COPD (48).  Furthermore, MNA was shown to be an independent 
predictor of FFMI, being significantly correlated with most other 
anthropometrics, lung function and exercise capacity indicators (37). 
SGA 
SGA of nutritional status has been validated as a screening tool to identify 
patients at risk of malnutrition (51). In Based on SGA, patients can be 
categorized as well nourished (Category A, SGA-A), mild/moderately 
undernourished (Category B, SGAB) or severely undernourished (Category C, 
SGA-C). SGA has been applied successfully as a method of assessing 
nutritional status in patients with several health-related conditions, i.e. cancer 
and dialysis, and correlated with objective parameters (anthropometric, 
biochemical and immunological), measures of morbidity, length of hospital 
stay, use of medications and quality of life. It also has a high degree of 
reproducibility (52). However, only few studies has been published on the use 
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of the SGA in COPD patients (53, 54), showing that SGA scores correlated 
positively with pulmonary function parameters and negatively with 
anthropometric parameters. 
Nevertheless, an important difference between the risk stratification 
diagram and these nutritional screening tools is that the latter primary focus on 
malnutrition and do not take abnormal body composition into account. 
2.2 Nutritional phenotypes in COPD 
Supporting the concept that body weight and body composition are part of the 
heterogeneity of the disease, and predictors of outcome independent of lung 
function impairment (27), a European Respiratory Society Task Force recently 
identified different nutritional phenotypes of COPD (i.e. cachexia, sarcopenia 
and sarcopenic obesity) (27).  
Cachexia 
Although often incorrectly perceived as end-stage malnutrition, the cachectic 
phenotype has been recently defined by weight loss (>5% in 6 months), reduced 
BMI and reduced muscle mass and function in combination with an underlying 
disease that displays biochemical indices of on-going elevated inflammatory 
activity (as revealed by for example increased serum CRP levels response) (29). 
Cachexia occurs frequently in patients with COPD, due to the catabolic 
inflammatory responses. Besides “generic” cachexia triggers including 
oxidative stress, inflammation, disuse and malnutrition, also disease specific 
determinants including hypoxia and glucocorticoids may play a role in 
particular during advanced disease. Furthermore, a muscle fiber type I to II shift, 
with a consequent decrease in oxidative capacity has also been observed in 
COPD (55).  
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Sarcopenia 
Sarcopenia is defined as a syndrome characterized by the progressive and 
generalized loss of skeletal muscle mass, strength and function (performance) 
with a consequent risk of adverse outcomes (29). According to European 
Working Group on Sarcopenia in Older Persons (EWGSOP) (56), the ESPEN 
Special Interests Groups of Cachexia in Chronic Disease and Nutrition in 
Geriatrics (57), diagnostic criteria for sarcopenia include loss of muscle mass 
and strength and/or function. In contrasts with EWGSOP international 
consensus statements, most studies describing sarcopenia in COPD have 
focused on only one aspect, predominantly the loss of skeletal muscle mass (58-
60), which is clearly considered insufficient. Only one paper examined 
sarcopenia in COPD using EWGSOP criteria (61), finding a prevalence of 
sarcopenia of 14.5%, which increased with age and GOLD stages   
Sarcopenic obesity 
Sarcopenic obesity is defined as obesity in combination with sarcopenia. 
Mechanisms include inflammation and/or inactivity induced muscle catabolism 
in obese patients (62). Currently, there are no commonly accepted criteria for 
sarcopenic obesity beyond those for sarcopenia and obesity separately (29). 
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3. Body composition in COPD 
The assessment of body composition has gained a central role into nutritional 
assessment of COPD patients. Indeed, several studies have shown the 
importance of adequate assessment of body composition in COPD patients (63).   
While originally considered an indicator of terminal progression of the 
disease, it is now well known in literature that unintentional weight loss is not 
an adaptive mechanism to decrease metabolic rate in advanced COPD (64) but 
an independent predictor of outcome independent of lung function impairment 
(24). 
Several measurements have been considered as potential prognostic 
indicators. For example, unintentional weight loss and low body mass index 
(BMI) are associated with significantly worse clinical outcomes (65). 
Nevertheless, muscle or fat-free mass measurements may be even better 
predictors of clinical outcomes (66), being associated with impaired physical 
performance. In addition, a pivotal role of osteoporosis and visceral adiposity 
in COPD risk and progression has emerged, which places the assessment of 
body composition as integral part of disease management (27). 
With this purpose, the method used is very important, but undoubtedly the 
criteria for this choice will depend not only on the advantages and disadvantages 
offered by each one, but also on the patient’s limitations, the conditions of the 
health system and the purpose of the study (67). 
Although there is no exact standard diagnostic procedure to evaluate body 
composition, different methods can be used in clinical practice: anthropometry 
(weight, height, skinfolds/circumferences measurements), bioelectric 
impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA) as well as 
more advanced imaging technologies like computed tomography (CT) and 
nuclear magnetic resonance (NMR). 
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3.1 Body mass index (BMI) 
Body mass index (BMI: body weight/height2) is a fairly reliable indicator of 
body fatness for most people. Hence, BMI is just a variable used to give some 
indications about body build or shape and about leanness or fatness. 
In COPD patients BMI is an important index of malnutrition and disease 
severity (68-70). Thus, either as a single measure or part of composite score – 
such as BODE index –, it remains a widely used variable in clinical practice 
(69, 71-73). 
Reduced BMI is seen in  COPD patients compared to control subjects (49, 
74-77). In the same way, an increased BMI has been described in chronic 
bronchitis patients compared to both emphysema patients and healthy control 
subjects (78). Several studies have reported a depletion in nutritional status of 
COPD patients in terms of  BMI <21 kg/m2 (34, 69, 70, 79-81), or <20 kg/m2 
(54, 74), or <22 kg/m2 (82). 
Low body mass index (<21 kg/m2) is related to poor exercise tolerance (83), 
low fat-free mass (FFM) (24) and co-morbid osteoporosis (84). Furthermore, it 
is incorporated in the prognostic assessment of COPD (71). On the other hand, 
high BMI (≥30 kg/m2) is related to increased dyspnoea (85), reduced weight-
bearing exercise performance (86) and systemic inflammation in COPD (24). 
At the same time, reductions in lung volumes have been consistently reported 
in obese COPD patients (87). 
BMI has been shown to be higher in GOLD stages I and II compared with stages 
III and IV. (50) In fact, low BMI is more prevalent (52%) in the subjects with 
severe COPD as compared to mild and moderate COPD (26.2%) (88).   
From a clinical point of view, in patients with moderate to severe airflow 
obstruction, a BMI <25 kg/m2 was consistently associated with increased 
mortality risk relative to overweight and even obese patients (65, 69, 89). This 
prognostic advantage of increased BMI in COPD, also referred to as the 
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‘‘obesity paradox’’, could be related to the direct effect of adipose tissue on lung 
mechanics (e.g. relative reduction in static volumes) in obese COPD patients 
(27, 90). 
Nevertheless, although considered a reliable indicator of body fatness for 
most people and an important indicator of malnutrition and disease severity in 
COPD patients (68, 70), weight changes and BMI do not take body 
compositional shifts, including FFM, appendicular skeletal muscle mass 
(ASM), fat mass (FM), fat distribution and bone mineral mass into account (27).  
In order to quantify the impact of COPD on the different body 
compartments further techniques are required. 
3.2 Fat-free mass (FFM)  
The two-compartment model of body composition divides body mass into FM 
and FFM. FFM can be further divided in an intracellular compartment, which 
includes muscle mass, bone mineral mass, and other metabolizing tissues, and 
an extracellular fluid compartment (91). FFM can also be expressed in 
absolute terms or as percentage of body weight. In COPD patients a height-
normalized index, called FFM index (FFMI) [FFM (kg)/height (m)2] is often 
used.  
In order to identify an abnormally low FFMI, several COPD-specific cut-
offs were reported in the last decades, based on well-established adverse effects 
of low FFMI on physical performance and survival (83, 92).  
A decrease of FFM was observed in 4 to 35% COPD patients and may occur 
independently of preserved or even increased BMI (83, 92).  
From a clinical perspective, low FFM of FFMI, independently of BMI and 
fat mass, may have adverse effects on health status (93), increasing the 
frequency or severity of acute exacerbations of the disease, and is a strong 
predictor of mortality (27, 94, 95).  
CHAPTER I 
26 
 
3.3 Appendicular skeletal muscle mass (ASM)  
Appendicular skeletal muscle mass (ASM), is the sum of the FFM of upper and 
lower limbs.  
Loss of ASM is frequent in COPD, with a prevalence of  nearly 30% among 
all patients, being higher in those with GOLD stage III-IV, compared to GOLD 
stage I-II (96). 
Among the factors that have been implicated as potential triggers of muscle 
wasting in COPD there are hypoxemia, malnutrition, inflammation and 
endogenous as well as synthetic glucocorticoids (21, 65, 97, 98).  
In addition to ASM depletion, several studies have also shown considerable 
modifications in the skeletal muscle histochemical characteristics. In general, 
biopsies of the quadriceps muscle have shown a reduced proportion of type I 
fibers and an increase in the proportion of type II fibers as compared with 
normal individuals (99, 100).  This change in fiber proportion reduces muscular 
oxidative capacity increasing fatigability and reducing muscle endurance (101). 
In fact, COPD patients had been found to show an altered fiber-type 
distribution, with a shift towards a higher proportion of type II fibers with 
respect to reported normal values (type I 56.7% and type II 43.3%) (102). The 
same study also demonstrates that in COPD patients’ health status – calculated 
using Saint George Respiratory Questionnaire (SGRQ) – correlates with 
peripheral muscle fiber type composition. This data suggest that worse health 
status is associated with less proportion of type I fibers which are fundamentally 
oxidative, indicating that pathophysiological changes in peripheral muscles may 
influence SGRQ total score independent of the degree of airflow limitation. 
Although several reference methods (DXA, CT, NMR) are available to 
evaluate lean tissues (ASM and FFM), BIA is a bedside approach, being widely 
investigated in clinical research due to the affordability, portability, and ease of 
use of bioimpedance devices (103-105).   
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Three predictive equations for the general population available in the 
literature (106-108) (no disease specific equation has been so far developed yet). 
Actually, while BIA has been used to estimate FFM in more than 100 papers on 
COPD (personal database) by using different predictive equations, to the best 
of the authors’ knowledge, only one paper used BIA to estimate ASM (61). 
3.4 Bone mineral density (BMD) 
Low bone mineral density (BMD) has been recognized as one the most common 
comorbidities of COPD. A recent meta-analysis of 13 studies in patients with 
COPD indicated the overall mean prevalence of low bone mineral density of 
35.1% (range 9–69%) (109). Proposed mechanisms that likely contribute to 
increased risk of low BMD in COPD include systemic inflammation, decreased 
physical activity owing to dyspnoea, low BMI, redunctions in pulmonary 
function and/or other factors leading to proteolysis, reduced bone formation and 
increased bone resorption (84, 110-113). Furthermore, pathogenetic links 
between adipose tissue and bone formation/destruction has recently emerged 
(114-116). Adiposity, expressed as FM index (FMI), was shown to be positively 
related to BMD, especially in non-obese patients (116). Both mechanical and 
endocrine effects of the adipose tissue seem to actively participate to the 
complex mechanism that regulate bone metabolism (115). Whereas most of the 
research on the association between fat mass and BMD has focused on total fat 
mass, it is not clear whether and to what extent abdominal fat, is associated with 
bone status. Abdominal fat mass was found to be associated with lower BMD 
(117). 
3.5 Body fat and body fat distribution 
The overall prevalence of obesity in a large primary care population of 
patients with COPD in the Netherlands has been found to be 18%, with the 
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highest prevalence in GOLD stages I and II (16–24%) and the lowest in GOLD 
stage IV (118).  
Generally speaking, in any given subject the effects of obesity on 
respiratory function depend on the anatomical distribution of the excessive body 
fat between upper and lower body (119). In healthy obese subjects, abdominal 
fat mass is recognized as a source for low grade systemic inflammation (defined 
by plasma CRP concentration) (120) and a determinant for cardiovascular risk 
(121). However, in spite of the wide interest in muscle mass and muscle 
wasting, only few studies have focused on body fat and body fat distribution in 
COPD.  
Rutten et al., carefully evaluated fat mass distribution in a large group of 
patients with moderate to severe COPD, demonstrating that patients with 
abdominal obesity had higher plasma CRP concentration,  diffusion capacity 
and FEV1/FVC. No differences in terms of the other lung function parameters 
were found in the same study, indicating no association between disease 
severity per se and abdominal FM between the patients with abdominal obesity 
and those without abdominal obesity. 
More specifically, within the abdominal region, visceral adipose tissue 
(VAT) is now recognized as a key feature of metabolic syndrome metabolic 
syndrome, diabetes, and cardiovascular disease (122-128). Furthermore, since 
cardiovascular disease is one of the main comorbidities in COPD, together with 
type II diabetes, skeletal muscle dysfunction and osteoporosis (24), VAT is 
receiving increasing attention in clinical assessment of COPD patients. 
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4. Muscle strength in COPD 
Loss of muscle strength (i.e. the ability to develop a maximal effort) or muscle 
weakness is highly prevalent in COPD. It is one of the most common and best 
studied systemic manifestations of COPD, being frequently associated with 
nutritional disorders (i.e. malnutrition) and nutrition-related conditions (i.e. 
sarcopenia). Muscle weakness can affect both respiratory and limb muscles,  
probably due to deconditioning, smoking, malnutrition, systemic inflammation, 
hypoxemia, hypercapnia/acidosis and some drugs such as steroids (129, 130). It 
carry several important consequences in COPD patients, such as poor quality of 
life, exercise intolerance, premature mortality and increased health care use 
(131). 
4.1 Respiratory muscles 
Respiratory muscles are those involved in ventilation and include inspiratory 
and expiratory muscles. The former, mainly consisting of the diaphragm, 
external intercostal and parasternal muscles, generate a more negative pleural 
and alveolar pressure with their contraction and allow the air to enter into the 
lungs. The latter are those located in the abdominal wall and the internal 
intercostals (129). In normal conditions, the relaxation of inspiratory muscles is 
sufficient to cause expiration, but when an extra expulsive effort is needed, 
expiratory muscles are recruited. This happens, for example, in the advanced 
stages of COPD. 
Many COPD patients show a reduction in the strength of respiratory 
muscles (132, 133), with a prevalence of 20–45%  in patients with a stable 
disease (133), and 80–90% in patients with frequent exacerbation (134).  
 Respiratory muscle weakness can be caused by malnutrition, hypoxemia, 
steroid myopathy or oxidative stress and requires a specific patient-addressed 
treatment based on nutritional supplements and muscle training (135). 
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4.2 Limb muscles 
Limb muscles are those involved in ambulation and other important activities 
of daily life and include muscles of the upper and lower extremities.  
Limb muscle weakness’s prevalence rate approximates 20% in patients with 
mild/moderate COPD and 40% in severe disease, with a loss of quadriceps 
strength of 25% (136), compared to healthy controls. Muscle weakness 
distribution among muscle groups is not homogeneous. In fact, the strength of 
the strength of upper limb muscles seems better preserved than that of lower 
limbs among patients with COPD (130, 137).  
Limb muscle strength is a determinant of physical activity and functional 
capacity in COPD (138). On the other hand, weakness is associated with poor 
outcomes such as exercise intolerance (139, 140), morbidity, mortality as well 
as increased health care service use, dyspnoea, and worse quality of life (93, 
141).  
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5. Tables and figures 
Table 1. Classification of airflow limitation severity in COPD 
 
 
Abbreviations: GOLD, Global initiative for chronic obstructive lung disease; 
FEV1, forced expiratory volume in 1 second; FVC; forced vital capacity. 
  
GOLD I: Mild FEV1/FVC < 0.70 and FEV1 ≥ 80% predicted 
GOLD II: Moderate FEV1/FVC < 0.70 and 50% ≤ FEV1 ≤ 80% 
predicted 
GOLD III: Severe FEV1/FVC < 0.70 and 30% ≤ FEV1 ≤ 50% 
predicted 
GOLD IV: Very severe FEV1/FVC < 0.70 and FEV1 ≤ 30% predicted 
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Table 2: Screening tools for rating the nutritional status of elderly patients 
 
Screening tool Clinical parameters Score 
MUST BMI 
Weight loss 
Presence of acute disease 
0, low risk of malnutrition; 1, 
medium risk of malnutrition; 
2, high risk of malnutrition 
NRS Age adjustment (≥70 years) 
Nutritional score: weight loss, changes 
in food intake, BMI, general condition 
Severity of disease score 
If score <3, absent, mild or 
moderate risk of malnutrition; 
if score≥3, severe risk of 
malnutrition 
MNA Nutritional status items: 
anthropometric, dietary, global and self-
rated status.  
Score between 24-30, normal 
nutritional status; score  
between 17–23.5 risk of 
malnutrition; score ≤ 16.5, 
malnourishment; score 
between  
SGA Questionnaire: weight loss, changes in 
dietary intake, gastrointestinal 
symptoms, functional capacity 
Physical examination: muscle, 
subcutaneous fat, sacral and ankle 
oedema, ascites 
Clinician’s overall judgement 
Stage A, well-nourished; 
stage B, moderate or 
suspected malnutrition; stage 
C, severe malnutrition 
 
Abbreviations: BMI, body mass index; MUST, Malnutrition Universal 
Screening Tool; NRS, Nutritional Risk Screening; MNA, Mini Nutritional 
Assessment and SGA, Subjective Global Assessment. 
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1. General and specific aims 
Given the important role of nutritional status as an independent determinant of 
outcome in COPD patients, this thesis has been carried out with the general aim 
of better understanding the occurrence of alterations of body composition and 
its relationship with muscle strength. 
In this perspective, a number of studies on COPD patients has been carried 
out with the specific aims of: 
- Systematically reviewing the use of bioelectrical impedance analysis (BIA) in 
the assessment of body composition and nutritional status. 
- Evaluating the prevalence of malnutrition and sarcopenia, as defined by the 
European Society for Clinical Nutrition and Metabolism (ESPEN), and to 
determine their relationship with functional parameters and raw BIA variables. 
- Evaluating body composition using multi-frequency (MF-BIA), in order to 
compare raw MF-BIA data between COPD patients and controls and to study 
their relationship with respiratory and functional parameters in COPD patients. 
- Studying the association of muscle strength with body composition estimates 
(i.e. FFM) and raw BIA data (i.e PhA), in order to better understand whether 
PhA is a predictor of HGS and respiratory muscle strength in COPD patients, 
independently from anthropometric variables and BIA-derived body 
composition estimates. 
- Assessing visceral adipose tissue using dual-energy x-ray absorptiometry 
determine its relation with disease severity, BMI, other indices of body 
composition and static lung volumes. 
2. Outline of the thesis 
The first study of the thesis is a systematic review, which aimed to 
investigate the use of BIA in COPD, in order to better understanding how to 
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interpret BIA data in these patients and how to apply BIA-derived body 
composition estimates for the diagnosis malnutrition or sarcopenia in COPD. 
The second study is cross-sectional study, which aimed to assess the 
prevalence of malnutrition and sarcopenia, as defined by the European Society 
for Clinical Nutrition and Metabolism (ESPEN), in COPD and to determine 
their relationship with functional parameters and raw BIA variables.  
The third study is a case-control study. The aim was to compare body 
composition, using a multi-frequency BIA, between COPD patients and 
controls and to study the relationship of raw multi-frequency BIA data  with 
respiratory and functional parameters in COPD patients. 
The fourth study is a cross-sectional study, which aimed to assess whether 
PhA, as a raw BIA data, is a  predictor of peripheral and respiratory muscle 
strength in COPD patients, possibly stronger than anthropometric variables and 
BIA-derived body composition estimates. 
The fifth study is a cross-sectional study carried out in order to determine 
the relation of VAT by dual- energy x-ray absorptiometry (DEXA) in patients 
with COPD by disease severity, BMI, other indices of body composition and 
static lung volumes. 
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Abstract 
Bioelectrical impedance analysis (BIA) is as widely used method for 
evaluating body composition in patients with chronic obstructive pulmonary 
disease (COPD). However, there is a considerable lack of information on how 
to apply BIA-derived body composition estimates in order to diagnose 
malnutrition or sarcopenia in COPD. Furthermore, it is not clear how to interpret 
raw BIA data in these patients. 
The aim of this study was to investigate the use of BIA in COPD, according 
to the Transparent Reporting of Systematic Reviews and Meta-Analysis 
(PRISMA) criteria. 
A review of original studies published between 1985 to 2016 was 
undertaken using PubMed and SCOPUS. 
Ninety-one  original papers were found to be relevant to the research. In the 
literature there were one COPD-specific BIA equation to predict total body 
water and four to predict fat-free mass (FFM). These latter was used in 35 
papers, while non-specific BIA equations were used in 9 papers and those 
provided by the manufacturer in 13. Twenty-three papers did not specify which 
equation was used. Fifty-four studies evaluated both FFM and FFM index 
(FFMI), 19 only FFM and 7 only FFMI. Appendicular skeletal muscle mass 
(ASMM) was evaluated with BIA in 5 papers. Only five papers provided data 
on raw BIA variables (in particular, 3 papers on phase angle, 1 paper on 
bioelectrical impedance index and 1 paper on multi-frequency impedance ratio). 
Finally, according to different diagnostic criteria, BIA derived FFM, FFMI or 
ASMM were used for identifying the occurrence of reduced skeletal muscle 
mass (6 papers), cachexia (7 papers) or sarcopenia (4 papers). 
Most studies did not used COPD-specific BIA equations to predict FFM in 
COPD patients. Although the increasing interest in the clinical setting, few data 
are available on raw BIA variables. Available data suggest that BIA may be 
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useful for diagnosing nutritional phenotypes such as cachexia or sarcopenia in 
COPD patients.  
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1. Introduction and aims 
Several studies have shown the importance of adequate assessment of body 
composition in COPD patients. The method used is very important, but 
undoubtedly the criteria for this choice will depend not only on the advantages 
and disadvantages offered by each one, but also on the patient’s limitations, the 
conditions of the health system and the purpose of the study (1). 
Although there is no exact standard diagnostic procedure to evaluate body 
composition, different methods can be used in clinical practice: anthropometry 
(skinfolds/circumferences measurements), bioelectric impedance analysis 
(BIA), dual-energy X-ray absorptiometry (DXA) as well as more advanced 
imaging technologies like computed tomography (CT) and nuclear magnetic 
resonance (NMR). 
Bioelectrical impedance analysis (BIA) is a simple, inexpensive, quick and 
non-invasive technique for evaluating body composition, widely used in 
patients with COPD. Like most body composition methods, BIA does not 
directly measure body composition, but provides indirect estimates from the 
measurement of resistance of body tissues to an electric current passing through 
the body (2-4).  
BIA variables directly measured by the analyzer are impedance (Z) and 
phase angle (PhA). Resistance and reactance are derived parameters. Z is 
resistance of the biological compartments to an alternating electric current (5). 
PhA reflects the relative contributions of fluid (resistance) and cellular 
membranes (capacitance) of the body (6). In addition, bioelectrical impedance 
index (BI index), calculated as squared height divided by impedance at 50 kHz, 
represents an established parameter of TBW(7). 
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1.1 Single frequency BIA 
Single frequency BIA (SF-BIA) devices measure impedance variables (i.e., Z, 
and PhA) at a single frequency, typically 50 kHz. 
SF-BIA is useful to estimate a body compartment (i.e. total body water, 
TBW and FFM) in patients with COPD, using several disease-specific 
predictive equations (8-11), which include BIA variables. However, general 
predictive equations and manufacturer's equations have also been frequently 
used. The choice of a prediction equation (from the abundant literature on the 
topic) that ideally matches the patient that he or she wishes to assess, is one of 
several limitations to the application of SF-BIA in the clinical setting (12).  
Alternatively, as suggested by a growing number of authors (12, 13), a 
potentially useful approach to the use of SF-BIA might be to use the raw data 
generated, in particular, PhA. 
1.2 Multifrequency BIA 
Multi-frequency BIA (MF-BIA) devices measure Z at several frequencies, 
usually in the range between 1-1000 kHz (13).  
Since at low frequency the current cannot pass through the cell membrane 
due to its capacitance, low frequency currents are conducted only through extra-
cellular water (ECW), whereas high frequency currents penetrate cell 
membranes and are thus used to estimate total body water (TBW) (14). As a 
consequence, high to low frequency impedance ratio (i.e. Z at 250 kHz / Z at 5 
kHz) is a raw MF-BIA variable which provides information on water 
distribution between intra and extra-cellular compartments and therefore on 
body cell mass and muscle quality (15-17).  
Although BIA is largely used both in research and in clinical practice, there 
is considerable lack of information on how to apply BIA-derived body 
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composition estimates in order to diagnose malnutrition or sarcopenia in COPD. 
Furthermore, it is not clear how to interpret raw BIA data in these patients. 
To our knowledge, no recent systematic review of the international 
scientific literature has been published yet. In this perspective, we aimed to 
systematically investigate the use of BIA in COPD, according to the 
Transparent Reporting of Systematic Reviews and Meta-Analysis (PRISMA) 
criteria. 
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2 Methods 
A systematic literature search was performed to identify published studies, 
which used BIA for assessing body composition in patients with COPD, using 
specified inclusion and exclusion criteria. 
2.1 Inclusion and exclusion criteria  
Type of studies 
Cross-sectional, case-control, longitudinal and intervention studies were 
included. If appropriate, reviews, case reports, editorials and comments were 
considered only for the discussion.  
Types of participants 
Studies assessing body composition using BIA in COPD patients of any age or 
nationality were considered. Studies on healthy controls were also included 
when compared to COPD. Studies involving samples of patients suffering from 
any respiratory disease different from COPD were excluded. 
Other criteria 
Studies included were limited to those published in the English language. We 
limited the search to articles regarding humans. Studies published in abstract or 
thesis format only were excluded. 
2.2 Search, screening and selection of included papers 
A comprehensive and systematic search of the literature was conducted on 
PubMed and Scopus by two independent reviewers, for relevant papers 
published from 1985 to August 2016, using the following keywords: “BIA or 
“biompedance” or “bioelectrical impedance analysis” and “chronic obstructive 
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pulmonary disease” or “COPD”. Additional publications were identified from 
references provided in original papers.  
Two reviewers screened the title and abstract of each study independently 
against the inclusion/exclusion criteria. 
Two reviewers then screened full texts of remaining articles against the 
review criteria. Where disagreements were acknowledged, a third reviewer 
made a final decision.  
2.3 Statistical analysis 
 Data from each included study were extracted and checked by two reviewers 
into standardised tables. Data extracted included information regarding sample 
characteristics, type of BIA device, raw variables measured, body 
compartments estimated, diagnosis of nutritional disorders, relation of body 
composition with respiratory function or other outcome. Statistical analysis was 
performed using SPSS version 20.0.  
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3 Results 
3.1 Description of the papers  
After checking for duplicates, 141 potential articles were initially included. Of 
those, 39 papers were excluded because they were not of interest or published 
in different languages from English. From the resulting 102 articles, 4 were 
excluded because they were reviews, 3 because conference papers, 1 because 
case report, 1 because book chapter and 1 because pilot study. Furthermore, one 
study was excluded after full-text review because of a not clear use of BIA for 
assessing body composition. None of the papers had a study design that could 
infer causality. Finally, 91 original papers met the review criteria (figure 1). An 
overview of the studies included in this review is reported in table 1.  
Study design 
Sixty-nine papers had a cross-sectional design, of which 22 had also a control 
group. Seventeen papers had a longitudinal design, 7 retrospective and 10 
prospective. Of these latter, 2 were also case control studies. Furthermore, a 
total of 5 intervention studies was included. 
Country of the study  
The majority of the studies presented data from Europe (23 Dutch, 6 Sweden, 6 
Norwegian, 5 Italian, 4 German, 3 French, 3 Polish, 2 Slovakian, 1 Czech, 1 
Danish, 1 Greek, 1 Romanian, 1 Spanish and 1 Swiss). Moreover, there were 8 
papers on Brazilian data, 8 on data from United Kingdom, 4 Chinese papers,  4 
from Japanese,  1 from Taiwan, 1 from Russia, 1 from Taiwan, 1 from USA. 
Furthermore, 3 multicentric studies were also analysed    
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3.2 BIA approach 
Fifty-five studies used a SF-BIA device, twenty-eight a MF-BIA device and 
four studies a BIS device. Four studies did not specified which approach they 
used. 
3.3 Body compartments estimated 
As reported in table 2, one COPD-specific BIA equation to predict total body 
water was found in the literature and four COPD-specific BIA equation to 
predict fat-free mass (FFM). These latter were used in 35 papers, while non-
specific BIA equations were used in 9 papers and those provided by the 
manufacturer in 13. Twenty-three papers did not specify which equation was 
used (figure 2).  
Fifty-four studies reported data on both FFM and FFM index (FFMI), 19 
only on FFM and 7 only on FFMI. Appendicular skeletal muscle mass (ASM) 
was evaluated with BIA in 5 papers, four of which also as ASMI (figure 3). 
3.4 Raw BIA data 
Finally, only five papers provided data on raw BIA variables. In particular, 1 
paper on BI index (18), 3 papers on phase angle (19-21) and 1 paper on multi-
frequency impedance ratio (22).  
3.5 Diagnosis of nutritional disorders 
According to different diagnostic criteria, BIA derived FFM, FFMI, ASM or 
ASMI were used for identifying the occurrence nutritional disorders, i.e. 
cachexia (7 papers) or nutrition-related conditions, i.e. sarcopenia (4 papers). 
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4 Discussion 
The present review has been carried out with the aim of systematically analyse 
the use of BIA for assessing body composition in COPD. With this purpose, 91 
original studies has been selected. 
There are different ways that BIA has been applied in COPD. i.e. using data 
generated by SF-BIA or MF-BIA or BIS devices. SF-BIA is the most widely 
used approach in literature, generally in order to obtain estimates of FFM or 
TBW. Compared with SF-BIA, MF-BIA was used in a smaller number of 
studies on COPD patients and, generally, in order to estimate within TBW, the 
volume occupied by intra-cellular water (ICW) and extra-cellular water (ECW) 
through predictive equations (18, 23). 
The present review has found that the 80% of the included studies, used 
BIA in order to estimate FFM (n=73) and, FFMI (67%; n=61), while a smaller 
percentage of papers, to estimate FM (47%; n=43) and FMI (29%; n=26).  
In the clinical setting, for estimating FFM, three disease specific BIA 
predictive equations were developed using DXA as reference method in studies 
that exclusively (10, 11) or predominantly(9) involved COPD patients. Schols 
et al. (8) also proposed a disease-specific predictive formula for TBW.   
This review has pointed out that, although the presence of several COPD-
specific BIA equations for predicting FFM, a number of studies did not use any 
of them, choosing equations provided for the general population instead. 
Furthermore, the great majority of studies found in literature did not specified 
which predictive equation was used. Manufacturer's equations have also been 
frequently applied.  
ASM, i.e. the sum of FFM of upper and lower limbs, has also been evaluated 
in COPD, although much less frequently compared to FFM. In fact, while BIA 
has been used to estimate FFM (as such or indexed to height, i.e. FFMI) in 
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almost all the papers included in this review, only 5 papers used BIA to estimate 
ASM by using several predictive equations for general population. In fact, 
differently from FFM, no disease specific equation has been so far developed 
yet.  As a matter of fact, evaluating ASM (and ASMI) is receiving increasing 
interest in clinical setting, since this variable is one of the diagnostic criteria for 
sarcopenia in older people (24).   
As described above, BIA is a widely used method for estimating body 
compartments in COPD. Alternatively, directly measured (i.e. raw) BIA 
variables are receiving increasing interest in the clinical management of COPD, 
providing direct information on cellular mass and integrity, without the 
assumptions inherent in estimating body compartments (21). However, only 5 
studies provided data on raw BIA variables, specifically focusing on PhA. 
Finally, body composition estimates derived from BIA (i.e. FFM and ASM) 
has been applied in order to diagnose nutritional phenotypes, such as cachexia 
or sarcopenia, in a small number of studies. Nevertheless, the choice of criteria 
used is not homogeneous among papers. The European Society for Clinical 
Nutrition and Metabolism (ESPEN) and the European working Group on 
Sarcopenia in Older People (EWGSOP) have recently provided valuable criteria 
for identifying cachexia and sarcopenia, respectively (24, 25). However, 
diagnostic criteria varied among COPD studies, being still debated. 
Concluding, available data in literature suggest that BIA has been widely 
used in order to assess body composition in COPD. However, very few data are 
available on raw BIA variables.  
Furthermore, although standardized and reproducible criteria should be 
applied, the results of the present study highlights that BIA may be useful for 
diagnosing nutritional phenotypes such as cachexia or sarcopenia in COPD 
patients.  
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5. Figures and Tables 
Figure 1. Flow chart of papers screened for this review 
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Table 1. Overview of the 91 studies included in this review 
FIRST AUTHOR 
(reference) 
YEAR BODY 
COMPOSITION 
ESTIMATED 
BY BIA 
RAW BIA 
VARIABLES 
PREDICTIVE 
BIA 
EQUATIONS 
ABBATECOLA (20) 2014 FFM, FM and 
FFM/FM 
PhA Piccoli et al., 1998 
(26) 
AL-SHAIR (27) 2009 FFMI - Not specified 
BAARENDS (18) 1998 ECW  and TBW BI index Not specified 
BROEKHUIZEN 
(28) 
2005 FFM, FM and 
FFMI  
- Steiner et al., 
2002 (10) 
BROEKHUIZEN 
(29) 
2006 FFM, FM and 
FFMI  
- Steiner et al., 
2002 (10) 
BROEKHUIZEN 
(30)   
2005 FFM, FM and 
FFMI 
- Schols et al., 1991 
for COPD (8) 
 
Lukaski et al., 
1985 for controls 
(31)  
BUDWEISER (32) 2008 FFM, FM, FFMI 
and FMI 
- Kyle et al., 2001 
(33) 
CAMILLO (34) 2008 FFM, FM, FFMI 
and FMI 
- Kyle et al., 1998 
(9) 
CREUTZBERG (35) 1998 FFM, FFMI and 
FM  
- Schols et al., 1991 
for COPD (8) 
 
Lukaski et al., 
1986 for controls 
(36) 
CREUTZBERG (37) 2003 FFM and FFMI -  Schols et al., 
1991 (8) 
DE BLASIO (22) 2016 FFM, FM, FFMI 
and FMI 
Impedance 
ratio 
Rutten et al., 2010 
(11) 
DI MARCO (38) 2013 FFMI and FMI - Not specified 
DORE' (39) 1997 FFM, FM, and 
ACM  
- Manufacturer  
EAGAN (40) 2010 FFMI and FMI - Not specified 
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EAGAN (41) 2012 FFMI and FMI - Schols et al., 1990 
(42) 
EISNER (43) 2007 FFM and FM  - Sternfeld et al., 
2002 (44) 
EMTNER (45) 2014 FFM and FFMI  - Not specified 
FAISY (46) 2000 TBW, ECW, 
ICW, FFM, FM 
and ACM 
- Boulier et al., 
1990 for FFM 
(47) 
 
Jenin et al, 1975 
for ECW (48) 
FRANSSEN (49) 2004 FFM, FFMI and 
FM 
-  Schols  et al., 
1991 (8) 
FRANSSEN (50) 2005 FFM, FFMI, FM 
and FMI 
-  Schols  et al., 
1991 (8) 
GIRON (51) 2009 FFM and FM - Manufacturer 
GODOY (52) 2000 FFM and FM - Schols et al., 1991 
(8) 
GOLOGANU (53) 2014 FFM, FFMI, FM, 
VAT, ASM and 
ASMI 
- Schols et al., 1991 
(8) 
GOSKER (54) 2003 FFM and FFMI - Schols et al., 1991 
for COPD (8) 
 
Lukaski et al., 
1985 for controls 
(31) 
GOSKER(55) 2002 FFM and FFMI - Schols et al., 1991 
(8) 
GROENBERG (56) 2005 FFM and FFMI - Manufacturer 
GURGUN (57) 2012 FFMI and FMI - Not specified 
HALLIN (58) 2011 FFM, FM, FFMI 
and TBW  
- Not specified 
HITZL (59) 2010 FFM, FM, FFMI 
and FMI 
- Kyle et al., 2001 
(33) 
HOPKINSON (60) 2007 FFM - Steiner et al., 
2002 (10) 
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HOPKINSON (61) 2008 FFM and FFMI - Steiner et al., 
2002 (10) 
HRONEK (62) 2013 FFM, FM, FFMI 
and FMI  
- Manufacturer plus 
Steinter et al. 
2002 (10) 
HSU (63) 2014 FFM, FFMI and 
FM 
- Not specified 
ISCHAKI (64) 2007 FFMI - Not specified 
JONES (65) 2015 ASM, ASMI - Janssen et al.,  
2000 (66) 
JOPPA (67) 2016 FFM, FM, FFMI 
and FMI 
- Steiner et al., 
2002 (10) 
KAYMAZ (68) 2015 FFM and FFMI - Not Specified 
KILDUFF (69) 2003 FFM  - Kyle et al., 1998 
(9) 
KOBAYASHI (70) 2000 FFM and FM - Not specified 
KUROSAKI (71) 2009 FFMI and FMI - Not specified 
KYLE (72) 2005 FFM, FFMI, FM 
and FMI  
- Kyle et al., 2001 
(33) 
LEI (73) 2014 FFM and FM - Manufacturer 
LENARTOVA (74) 2016 VAT - Not specified 
LERARIO  (1) 2006 FFM, FM and 
FFMI 
- Schols et al., 1991 
(8) 
LIU (75) 2009 FFM and FM - Manufacturer 
LUO (76) 2005 FFM, FM - Manufacturer 
LUO (77) 2016 FFMI - Not specified 
MADDOCKS (21) 2015 FFM, FFMI PhA Not Specified 
MAMOTO (78) 2003 TBW, ICW, 
ECW, upper 
extremity water, 
trunk water, lower 
extremity water 
and FM 
- Not specified 
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MARINARI (79) 2013 FFMI and FMI - Not specified 
MEKAL (80) 2015 FFM, FM, FFMI 
and TBW 
- Not Specified 
MILLER (81) 2009 FFM, FM, FFMI, 
FMI and TBW 
- Schols et al., 1991 
(8) plus Lukaski 
et al., 1985 (31) 
MONTEIRO (82) 2012 FFM, FM and 
FFMI  
- Kyle et al., 1998 
(9) 
MOSTERT (83) 2000 FFM and FFMI - Schols et al., 1991 
(8) 
MULLER (19) 2006 FFM, FM, FFMI, 
FMI, BCM, ECM 
and ECM/BCM  
PhA Not specified 
NORDEN (84) 2015 FFM and FFMI - Manufacturer 
NORDENSON (85) 2010 FFM and FFMI - Manufacturer 
PERSSON (86) 2015 FFMI and FMI - Not Specified 
RAMIRES (87) 2012 FFM, FM, ASM 
and ASMI 
- Segal et al., 1988 
for FFM (88) 
  
Janssen et al., 
2000 for ASM 
(66) 
RUBINSZTAJN (89) 2014 FFM, FM and 
FFMI 
- Not specified 
RUBINSZTAJN (90) 2015 FFM, FM, FFMI 
ASM, ASMI and 
TBW 
- Not Specified 
RUTTEN (11) 2010 FFM and FFMI - Steiner et al., 
2002 (10) 
RUTTEN (91) 2011 FFM, FM, FFMI 
and FMI 
- Rutten et al., 2010 
for COPD (11) 
 
Dey et al., 2003 
for controls (92) 
SABINO (93) 2010 FFMI and FMI - Kyle et al., 1998 
(9) 
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SANCHEZ (94) 2011 FFM and FFMI - Kyle et al., 1998 
(9) 
SAURE (95) 2012 FFMI and FMI - Not specified 
SCHOLS (42) 1990 FFM and Rx - Schols et al., 1990 
(42) 
SCHOLS (8) 1991 FFM and TBW - Schols et al., 1991 
(8) 
SCHOLS (96) 2005 FFMI FMI and 
ASMI 
- Schols et al., 1991 
for FFM (8) 
 
Janssen et al., 
2000 for ASM 
(66) 
SCHOLS (97) 1991 FFM - Schols et al., 1991 
(8) 
SCHOLS (98) 1991 FFM  - Schols et al., 1990 
(42) 
SCHOLS (99) 1993 FFM and ASM  - Schols et al., 1990 
(42) 
SCHOLS (100) 1996 FFM, FFMI and 
FM 
- Schols et al., 1991 
(8) 
SERRES (101) 1998 FFM - Schols et al., 1991 
(8) 
SEYMOUR (102) 2009 FFM and FFMI - Steiner et al., 
2002 (10) 
SILVEIRA (103) 2014 FFM and FFMI - Schols et al., 1991 
(8) 
SLINDE (104) 2005 FFM and FFMI  - Manufacturer 
STEINER (10) 2002  FFM and FFMI  - Steiner et al., 
2002 (10) 
STEUTEN (105) 
 
2006 FFMI - Not specified 
TEOPOMPI (106) 2013 FFM and FFMI  - Segal et al., 1988 
(88) 
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TKACOVA (107) 2010 FFMI and FMI - Not specified 
VAKHLAMOV 
(108) 
2015  FM and VAT - Not Specified 
VERMEEREN (109) 2006 FFM, FM, FFMI 
and FMI 
- Steiner et al., 
2002 (10) 
VERMEEREN (110)  1997 FFM, ICW and 
ECW 
- Not specified 
VESTBO (111) 2006 FFM, FM and 
FFMI 
- Segal et al., 1988 
(88) 
VILARO' (112) 2010 FFM, FM and 
TBW 
- Not specified 
VRIEZE (113) 2007 FFM and FFMI - Not specified 
WAATEVIK (114) 2012 FFM, FM, FFMI 
and FMI 
- Not specified 
WAATEVIK (115) 2016 FFM, FM, FFMI 
and FMI 
- Not specified 
WATZ (116) 2008 FFM and FFMI - Not specified 
YOSHIKAWA (23) 2012 ICW, ECW and 
ECW/ICW 
- Not specified 
 
Abbreviations: FFM, fat-free mass; FM, fat mass; FFMI, FFM index; FMI, FM index, BI 
index, bioelectrical impedance index; ECW, extra-cellular water; ICW, intra-cellular water; 
TBW, total body water; ACM, active cell mass; VAT, visceral adipose tissue; ASM, 
appendicular skeletal muscle mass; ASMI, ASM index, PhA, phase angle; BCM, body cell 
mass.  
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Table 2. Details of four disease-specific equations with BIA variables to 
calculate body composition in patients with COPD 
 
 
 
  
Author Population   Validation 
method 
FFM predictive equation 
Schols et al.,  
Am J Clin 
Nutr, 1991 
24 M, 65±10 years 
8 F, 57±11 years 
TBW M and F: 
3.32 + 0.44×Ht
2
/R + 
0.13×Wt)/0.73 
Kyle et al.,  
Eur Respir J, 
 1998 
60 M, 66.8±8.2 years 
15 F, 60.8±11.,1 years 
DXA M and F: 
6.06 + 0.83×Ht + 0.207×Wt − 
0.024×R (+ 4.036  if M) 
Steiner et al., 
Eur Respir J,  
2002 
53 M, 67.7±8.4 years 
 32 F, 65.6±8.7 years 
DXA M: 8.383 + 0.465×Ht
2
/R  
+ 0.213×Wt 
F: 7.610 + 0.474×Ht
2
/R  
+ 0.184×Wt 
Rutten et al.,  
Resp Med, 
2010 
641 M, 65.4±9.4 
years 
446 F, 60.1±9.3 years 
DXA M and F:  
−11.81 + 0.245×Wt + 
0.298×Ht
2
/R + 0.148×Ht 
 (+ 5.284 if M) 
 
Abbreviations: M, males; F, females; Ht, height; Wt, weight; BMI, body mass index; 
R, resistance 
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Figure 2. Number of papers that estimated fat free mass with several BIA 
predictive equation available in the literature. 
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Figure 3. Estimates of body composition derived from BIA  
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Abbreviations: FFM, fat-free mass; FFMI, FFM index; FM, fat mass; FMI, FM index; ASM, 
appendicular skeletal muscle mass; ASMI, ASMM index. 
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Table 3.  List of studies, which used BIA for assessing cachexia 
Author BIA 
equation 
used 
Number of 
subjects 
Criteria to define 
cachexia 
Prevalence of 
cachexia 
Schols et al., 
2005(117) 
Schols et 
al.(8) 
412 COPD 
(317 M and 95 
F) 
BMI <21 kg/m2 plus 
FFMI<16 kg/m2 in M 
or <15 kg/m2 in F 
(118) 
28.5% (29.0% in M 
and 27.0% in F) 
Broekhuizen 
et al., 
2005(119) 
Schols et 
al.(8) 
99 COPD (69 
M and 30 F) 
20 controls (15 
M and 5 F) 
FFMI<16 kg/m2  in 
M or <15 kg/m2 in F  
35.4% in COPD 
Eagan et al., 
2010(120) 
Not 
specified 
409 COPD 
(249 M and 
160 F) 
FFMI<17 kg/m2 in M 
or <14 kg/m2 in F 
(121) 
29.1% (31.0% in M 
vs 27.5% in F) 
Eagan et al., 
2012(41) 
Not 
specified 
408 COPD 
(249 M and 
159 F) 
FFMI<17 kg/m2 in  
M or <14 kg/m2 in F 
(121) 
28.7% (31.0% in M 
and 27.5 in F) 
Gologanu et 
al., 2014 (53) 
Not 
specified 
36 COPD (33 
M and 3 F) 
BMI ≤ 21 kg/m2 and 
FFMI ≤ 16 kg/m2 in 
M and ≤14 in F. 
8.3% 
Persson et al., 
2015 (86) 
Not 
specified 
526 COPD  FFMI<17 kg/m2 in M 
or <14 kg/m2 in F 
(121) 
31.7% vs 26.8% in 
patients with 
Vitamin D 
deficiency vs those 
without and 29.7%, 
27.1% and 29,4% in 
those with VDBP 
<200 μg/mL, 
between 200 and 
299 μg/mL and > 
300 μg/mL, 
respectively. 
Waatevik et 
al., 2015 
(115) 
Not 
specified 
370 COPD 
(223 M and 
147 F) 
FFMI<17 kg/m2 in M 
or <14 kg/m2 in F 
(121) 
27.0% (25.5% in 
patients with 
desaturation during 
6MWT vs 74.5% in 
those without 
desaturation) 
 
Abbreviations: BMI, body mass index; FFMI, fat-free mass index; VDBP, 
vitamin D binding protein; 6MWT, 6-minute walk distance. 
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Table 4.  List of studies, which used BIA for assessing sarcopenia 
 
 
Abbreviations: ASMI, appendicular skeletal muscle mass index; BMI, body mass index; 
FFMI, fat-free mass index; EWGSOP, European working group on sarcopenia in older 
people. 
Author BIA 
equation 
used 
Number of 
subjects 
Criteria to define 
sarcopenia 
Prevalence of 
sarcopenia 
Ramires et 
al., 
2012(87) 
Janssen et 
al.(66) 
20 COPD 
20 controls 
5.76<ASMI<6.75 or 
ASMI ≤5.75 kg/m2 in 
F; 8.51<ASMI<10.75 
or ASMI≤8.50 kg/m2 
in M; to denote 
moderate or high 
physical disability risk, 
respectively (122) 
Not assessed 
Gologanu 
et al., 2014 
(53) 
Not 
specified 
36 COPD (33 M 
and 3 F) 
BMI > 21 kg/m2 and 
FFMI ≤ 16 kg/m2 in M 
and ≤15 kg/m2 in F. 
8.3% 
Jones et al., 
2015 (65) 
Not 
specified 
622 COPD (354 
M and 268 F) 
EGWSOP (24) 14.5% (16.1% 
in M  vs 
12.3% in F) 
Joppa et al., 
2016 (67) 
Steiner et 
al.(10) 
2000 COPD 
(1314 M and 
686 F) 
548 controls 
(272 M and 276 
F) 
FFMI < 10th percentile 
of age, sex, and BMI-
specific reference 
values (123) 
24.0% in 
COPD 
15.0% in 
controls 
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Table 5. List of studies, which used raw BIA variables  
Author Number of 
subjects 
BIA 
approach 
(SF, MF 
or BIS) 
BIA 
variable 
Mean values 
Baarends et 
al., 1998 
(18) 
40 COPD (32 M 
and 8F) 
BIS BI index 36.2 cm2/ohm in M and 
28.9 cm2/ohm in F 
Muller et al., 
2006 (19) 
164 COPD (100 M 
and 64 F) 
120 controls (56 M 
and 64 F) 
MF PhA 4.4 and 4.5 degrees in 
M and F with COPD; 
5.8 and 5.5 degrees in 
M and F controls 
Abbatecola 
et al., 2013 
(20) 
132 COPD (86 M 
and 46 F) 
SF PhA 5.5 and 4.7 degrees in 
M and F  
Maddocks et 
al., 2015 
(21) 
502 COPD (295 M 
and 207 F) 
MF PhA 4.7 degrees (4.9  
degrees in M and 4.3 
degrees in F) 
De Blasio et 
al., 2016 
(22) 
212 COPD (144 M 
and 68 F) 
115 controls (53 M 
and 62 F) 
MF IR 124.1 and 122.3 in M 
and F with COPD; 
126.8 and 126.0 in M 
and F controls 
Abbreviations: BIS, bioelectrical spectroscopy; MF, multi-frequency; SF, single frequency; 
BI index, bioelectrical impedance index; PhA phase angle; IR, impedance ratio  
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Abstract 
Malnutrition and sarcopenia are two major consequences of chronic obstructive 
pulmonary disease (COPD). However, no previous study focused on the 
prevalence of overlapping malnutrition and sarcopenia in these patients. 
The aim of this study was to determine the prevalence of malnutrition and 
sarcopenia, as defined by the European Society for Clinical Nutrition and 
Metabolism (ESPEN), in COPD and to determine their relationship with 
functional parameters and raw BIA variables. 
Two-hundred and sixty COPD patients (183 males and 77 females) 
underwent respiratory, anthropometric, bioelectrical impedance analysis (BIA), 
handgrip strength (HGS), six-minute walk distance (6MWD) and biochemical 
measurements. Malnutrition was diagnosed based on low body mass index 
(BMI <18.5 kg/m2) or between 18.5 - 22.0 kg/m2, plus low fat-free mass index 
(FFMI<17 kg/m2 for males and <15 kg/m2 for females). Malnourished patients 
with CRP levels>5 mg/dL were defined as cachectic. Sarcopenia was diagnosed 
as low appendicular muscle mass plus low HGS or 6MWD (or both, in case of 
severe sarcopenia). 
The overall prevalence of malnutrition and sarcopenia was 20.4% and 
25.4% respectively, being significantly higher across global initiative for 
chronic obstructive lung disease (GOLD) stages. Nor malnutrition or sarcopenia 
differed by age. The prevalence of sarcopenia was significantly higher in 
patients with malnutrition and, among malnourished patients, in those with 
inflammation (cachexia). Among malnourished patients, a significant reduction 
in BMI, forced expiratory volume in 1 second, inspiratory capacity/total lung 
capacity, FFM, HGS emerged in those with sarcopenia, compared to non 
sarcopenic patients. 
In conclusion, we identified a 20.4% prevalence of malnutrition and a 
25.4% prevalence of sarcopenia in patients with COPD. A clear discrepancy 
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between the two conditions emerged, since 42.4% of sarcopenic patients do not 
fulfil the ESPEN criteria of malnutrition. An association of the presence of 
malnutrition and sarcopenia with GOLD stages also emerged, with a prevalence 
of the two conditions (separately or combined) that increased with disease 
severity.  
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1. Introduction and aims 
COPD is a heterogeneous disease not only in terms of pulmonary characteristics 
but also with respect to both systemic consequences such as weight loss and 
muscle weakness, and co-morbidity (e.g. osteoporosis, diabetes and 
cardiovascular disease) (1). Malnutrition and nutrition-related phenotypes (for 
example, sarcopenia) are highly prevalent extra-pulmonary manifestations, 
which are associated with important consequences for health risk assessment, 
stratification and management of the disease (2). For this reason, early diagnosis 
of both malnutrition and sarcopenia are highly recommended. 
Malnutrition is more common in advanced GOLD stages (3) and in acute 
exacerbations compared to stable COPD (4). Indeed, wide difference in the 
prevalence of malnutrition in COPD patients, as found in the literature, may also 
be expected due to the use of different diagnostic criteria. Overall, the definition 
of standardized approaches for identifying malnourished patients is a key issue 
in clinical nutrition. In the last few years, international criteria for the diagnosis 
of malnutrition were defined by the American Society of Parenteral and Enteral 
Nutrition (ASPEN) together with the Academy of Nutrition and Dietetics (5) 
and, more recently, by the European Society of Clinical Nutrition and 
Metabolism (ESPEN) (6). According to these latter, malnutrition is diagnosed 
based on low body mass index (BMI) or combined weight loss plus low BMI or 
low fat-free mass index (FFMI). In addition,  the ESPEN consensus statement 
(2016) recognized a disease-related malnutrition with inflammation (or 
cachexia) and a disease-related malnutrition without inflammation (no 
cachexia), depending on the presence of biochemical indices of either ongoing 
or recurrent inflammation. ESPEN criteria have been recently applied in several 
kind of patients, such as acutely ill middle-aged and diabetic hospitalized older 
patients, geriatric outpatients, geriatric post-acute care settings, healthy old and 
healthy young individuals (7, 8), finding out a prevalence of malnutrition from 
0-14% in the diverse populations, but never in in COPD. 
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Sarcopenia, which is another systemic manifestation of COPD (9),  is a 
syndrome characterized by the progressive and generalized loss of skeletal 
muscle mass, strength and performance with an increased risk of adverse 
outcomes (10-12). Widely accepted criteria for sarcopenia have been developed 
by the European Working Group of Sarcopenia in Older People (EWGSOP), 
recently endorsed by the ESPEN (6), and include an algorithm based on loss of 
appendicular muscle mass (ASM) plus reduced strength and/or performance 
(10, 13). However, in contrast with international consensus statements for 
sarcopenia, most studies on COPD have focused just on one aspect of 
sarcopenia (14-22), the loss of muscle mass, and only one paper on reduced 
muscle mass, strength and performance (23). 
Overall, only few studies focused on the overlapping presence of 
malnutrition and sarcopenia (8), suggesting a relation between these two 
conditions. Nevertheless, no study previously has been carried out in COPD.   
Thus, the aim of the present study was to determine the prevalence of 
malnutrition and sarcopenia, as defined by ESPEN, in COPD and to determine 
their relationship with functional parameters and raw BIA variables.  
2. Methods 
2.1 Subjects 
A cross-sectional study in consecutive hospitalized COPD patients was carried 
out in the Pulmonary Rehabilitation Section of Clinic Center S.p.A (Naples, 
Italy). This unit focusses on rehabilitation and recovery during a defined period 
of time, usually about 6 weeks before a scheduled home discharge. 
The study population consisted of 260 consecutive COPD patients, which 
met the following inclusion criteria: age >50 years and a baseline post-
bronchodilator forced expiratory volume in 1 second (FEV1)⁄forced vital 
capacity (FVC) < 0.7. Exclusion criteria were related to diagnosis of known 
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respiratory disorders other than COPD, known history of significant 
inflammatory disease other than COPD and a COPD exacerbation within 4 
weeks of enrolment. The Ethics Committee of the “Federico II” University of 
Naples approved the research protocol and all patients gave informed consent 
to participate in the study. 
2.2 Lung function  
All COPD patients performed a baseline post-bronchodilator spirometry and 
body plethysmography (QBOX® COSMED) according to American Thoracic 
Society (ATS)/European Respiratory Society (ERS) standardization (24). FEV1 
and FVC were assessed in accordance with the latest GOLD guidelines (25).  
Patients were classified into four stages according to the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) criteria.  If FEV1 ≥ 80% of the 
predicted, patients were classified as GOLD stage I (mild), if 50% ≥ FEV1 >80% 
of the predicted, as GOLD stage II (moderate), 30% ≥ FEV1 >50%  of the 
predicted as GOLD stage III (severe), and if <30% of the predicted as  GOLD 
stage IV (very severe). Inspiratory capacity (IC) and total lung capacity (TLC), 
were assessed. IC/TLC ratio (26) was calculated by dividing IC for TLC, and 
was used as a marker for hyperinflation, the abnormal increase in the volume of 
air remaining in the lungs at the end of spontaneous expiration (27). 
2.3 Body composition 
Body weight and body height were measured to the nearest 0.1 kg and 0.5 cm 
respectively, using a mechanical column scale (SECA 711+220; Hamburg - 
Germany), and BMI was calculated as body weight⁄height.2 Body composition 
was assessed by performing a multifrequency BIA in standardized conditions 
(i.e. ambient temperature between 23 and 25°C,  fast of > 3 h, empty bladder, 
supine position for at least 10 minutes before starting the measurement), using 
a Human Im-Touch analyzer (© DS Medica S.r.l., Milan, Italy). In addition, 
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after cleaning skin surface, patients were asked to lay with legs and arms slightly 
abducted at 30° so there was no contact between the extremities and trunk.  
A standard tetra-polar technique was used, with measuring electrodes 
placed on the anterior surface of the wrist and ankle, and injecting electrodes 
placed on the dorsal surface of the hand and the foot, respectively. Z and phase 
angle were obtained at five frequency kHz for both dominant (D) and non-
dominant (ND) sides with an imperceptible electrical current of 800 mA. In 
addition, bioelectrical impedance index (BI index) was calculated as squared 
height divided by impedance at 50 kHz, representing an established parameter 
of total body water (TBW) (28).  The impedance ratio between high (250 kHz) 
to low (5 kHz) and phase angle at 50 kHz, expressed as a degree, provide 
information on hydration status, cellular mass and quality (29, 30). FFM and 
FFM index (FFMI kg/m2 = FFM/height2) were estimated from Z at 50 kHz using 
a disease specific BIA equation (31). Appendicular skeletal muscle mass (ASM) 
was estimated using a BIA equation for general population (32). 
2.4 Diagnosis of malnutrition 
Malnutrition was diagnosed according to the main outcome variables indicated 
by the latest ESPEN consensus (6, 13). Patients were classified as malnourished 
when they had BMI<18.5 kg/m2 or BMI between 18.5 and 22 kg/m2, combined 
with low FFMI (<17 kg/m2 for men and <15 kg/m2 for females). In absence of 
elevated serum CRP concentrations (CRP<5 mg/dL), patients were defined as 
affected by malnutrition without inflammation. On the contrary, the 
simultaneous presence of elevated serum CRP concentrations (CRP ≥5 mg/dL), 
combined with malnutrition, was used for diagnosis of cachexia (or 
malnutrition with inflammation) (13). 
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2.5 Diagnosis of sarcopenia 
Sarcopenia was diagnosed in accordance with EWGSOP criteria (10). Patients 
with low muscle mass without impact on muscle strength or physical 
performance were classified as pre-sarcopenic. Patients were classified as 
moderately sarcopenic, when affected by low muscle mass, plus low muscle 
strength or low physical performance. Severe sarcopenia was identified when 
all three criteria of the definition were met (low muscle mass, low muscle 
strength and low physical performance).  
Low muscle mass was assessed by BIA as described above.  
Low muscle strength was assessed by handgrip strength, a surrogate 
measurement of overall muscle strength (33), measured at baseline with a digital 
hand-held dynamometer (Dynex, MD systems Inc. Ohio USA) and expressed 
in kilograms. Patients performed a maximum voluntary isometric contraction of 
finger flexor muscles. Three measurements were taken for both body sides 
(dominant and non-dominant). Mean value of the two body sides was indicated 
as whole body HGS (or HGS). The maximum values were considered for 
statistical analysis (34).  
Physical performance was assessed with 6-minute walk distance (6MWD) 
test in patients who were able to walk at baseline (35). Participants were 
instructed to stand with both feet touching the starting line and, after a verbal 
command, to begin walking with usual aids (canes or walkers) and at their usual 
pace. 
For the purpose of this analysis, low walking speed was defined as walking 
slower than 250 m, as previously indicated by Celli et al (36). 
2.6 Statistical Analysis 
Data are presented as mean (SD) or percentage (%). The prevalence of 
malnutrition and sarcopenia, with 100% of cells greater than 5, was determined 
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and compared according to gender, age and GOLD staging, using a non-
parametric test (Chi Square test for categorical variables, i.e. gender and GOLD; 
Mann-Whitney U Test for continue variables, i.e. age). P values less than 0.05 
were considered as statistically significant. SPSS 20.0 (IBM Corporation, SPSS, 
INC., Chicago, IL, USA) was used for data analyses. 
3. Results 
Two hundred and sixty patients (183 males and 77 females) with stable COPD 
were studied.  
3.1 Prevalence of malnutrition and sarcopenia 
The overall prevalence of malnutrition was 20.4% (53 patients). Prevalence did 
not differ either between genders (p=0.281) or age (p=0.71), but significantly 
increased among GOLD stages (11.2%, 18.0% and 32.5% in GOLD I+II, III 
and IV, respectively). There were 20 malnourished patients with inflammation 
(12.7% of total group) and 33 malnourished without inflammation (7.7%). 
Pre-sarcopenia was diagnosed in 4 out of 260 patients (1.5 %), who were 
grouped together with non-sarcopenic patients for this study.  The overall 
prevalence of sarcopenia was 25.4% (66 patients). Of these, 22 patients had a 
moderate sarcopenia and 44 had a severe sarcopenia. Low muscle mass was 
combined with low muscle strength (low HGS) in 54 patients or with low 
physical performance (low 6MWD) in 56 patients. Prevalence of sarcopenia 
was significantly higher in males compared to females (32.8% and 7.8%, 
respectively; p<0.001), and significantly different among GOLD stages (7.5%, 
22.0% and 47.5% in GOLD I+II, III and IV, respectively; p<0.001), but did not 
differed by age (p=0.61).  
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3.2 Characteristics associated with malnutrition  
General and body composition characteristics of 260 patients stratified for 
grades of malnutrition and sarcopenia are shown in tables 2 and 3, respectively. 
Malnourished patients with and without inflammation did not differ 
compared to each other, but exhibited lower values of weight, BMI, FFM, FM 
and ASM (p<0.05), compared to non-malnourished (table 1).  
Lower values of FEV1 (% pred) were found in malnourished patients with 
inflammation, compared to non malnourished patients (p=0.003). However, no 
significant difference was reported in malnourished patients without 
inflammation compared to the other two groups of patients, with different 
grades of malnutrition. A significant reduction of IC/TLC was also observed 
both in malnourished patients with (p=0.001) and without (p=0.01) 
inflammation, compared to non-malnourished (table 1). 
HGS was significantly lower in malnourished patients with inflammation, 
compared to non malnourished (p=0.001), although no differences emerged 
between malnourished patients with and without inflammation (table 2). 
With respect to raw BIA data, high to low frequency impedance ratios 
(specifically, 250/5 kHz  IR and 100/5 kHz IR) were significantly higher in 
malnourished patients with inflammation compared to non-malnourished 
patients (p=0.005) and, within the group of malnourished patients, significantly 
higher in those with inflammation, compared to those without (p=0.05). 
Similarly, PhA was significantly lower in malnourished patients with 
inflammation, compared to non-malnourished (p=0.001). Within the group of 
malnourished patients, PhA tended to be lower in those with inflammation 
compared to those without (p=102) (table 1). 
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3.3 Characteristics associated with sarcopenia 
With respect to grades of sarcopenia, both patients with moderate or severe 
sarcopenia exhibited lower values of height, weight, BMI, FM and ASM, 
compared to non-sarcopenic patients.. Differently, FFM was found to be 
significantly reduced only in severe sarcopenic patient, compared to non-
sarcopenic. 
A significant reduction of FEV1 and IC/TLC was also observed both in 
patients with moderate (p<0.001) and severe (p<0.01) sarcopenia, compared to 
non-malnourished (table 2). 
With respect to muscle strength, lower values of HGS emerged in patients 
with moderate (p<0.001) and severe (p<0.001) sarcopenia, compared to non-
sarcopenic patients (table 2). 
Similarly to what emerged across grades of malnutrition, differences in raw 
BIA data emerged also across grades of sarcopenia: higher values of 250/5 kHz  
IR, 100/5 kHz IR and 50/5 kHz IR emerged  in patients with severe sarcopenia, 
both compared to those with moderate sarcopenia and to non-sarcopenic 
patients (table 2). Likewise, a significant reduction in PhA values emerged only 
between sever sarcopeia and non-sarcopenic patients. 
3.4 Characteristics of malnourished patients, with and without sarcopenia 
The cross tabulation data of malnutrition and sarcopenia are shown in table 
3. The prevalence of sarcopenia was significantly higher in patients with 
malnutrition: 71.7% vs 13.5% (p<0.001). Among malnourished patients, the 
prevalence of sarcopenia was still higher in those with inflammation (cachectic), 
compared to those without (non-cachectic) (80.0% vs 63.6%; p<0.001)  
Table 4 shows general and body composition characteristics of 53 
malnourished COPD patients, divided in those with and without the 
simultaneous presence of sarcopenia. With respect to disease severity, 35 out of 
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38 malnourished patients with sarcopenia had a GOLD stage III/IV.  Compared 
to those without sarcopenia, malnourished patients with sarcopenia exhibited a 
significant reduction in FEV1 (28.7±12.1 vs 50.5±24.1, p<0.001), CI/CPT 
(0.15±0.05 vs 0.20±0.07, p=0.004), FFM (37.6±4.1 vs 41.2±3.6, p=0.004) and 
FFMI (data not shown). A similar tendency to be reduced emerged also for raw 
BIA variables. Not any reduction emerged with respect to FM. Indeed, when 
indexed to height, FMI was even higher in malnourished patients with 
sarcopenia compared to non-sarcopenic patients (data not shown).  
3.5 The high IR and low PhA group of patients 
Fifty-one patients (19.6%) had an IR above the 75° percentile (>0.834) and a 
PhA below the 25° percentile (<4.3 degrees) and were defined as those with 
worst muscle quality. Within this group of patients, the prevalence of 
malnutrition was 27.5% (14 out of 51 patients), and slightly differed from the 
rest of the COPD patients (18.7%, 39 out of 209 patients; p=0.07). The 
prevalence moderate/severe sarcopenia was 35.3% in the group of patients with 
highest IR and lowest PhA (18 out of 51 patients), and tended to be different 
compared to the rest of the COPD patients (23.0%, 48 out of 209 patients; 
p=0.07).  
Differences between the two groups of patients, stratified according to IR 
and PhA values, accentuate when considering only GOLD stages III and IV 
patients (table 5). 
4. Discussion 
The present study provides data on overall prevalence of malnutrition as 
defined by ESPEN (13) and sarcopenia according to the EWGSOP criteria (10) 
in COPD patients. Furthermore, this is the first study that focused concurrently 
on the presence of both conditions, highlighting their effects on clinical 
characteristics of these patients. 
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Malnutrition is a common and serious problem in COPD. It’s prevalence 
has been reported to vary between 10 and 60% for the entire COPD group, 
divided into 10-45% of outpatients and 30-60% of COPD inpatients (37), 
possibly due to varying definitions and criteria of malnutrition used (38). 
According to the ESPEN (6, 13), malnutrition can be diagnosed based on 
low BMI, low FFMI and loss of body weight. In addition, the latest 2016 
ESPEN consensus statement (13) proposed two different concept of disease-
related malnutrition, i.e. with inflammation (also indicated as cachexia) and 
without inflammation, based on the simultaneous presence of an underlying 
disease and/or biochemical indices of either ongoing or recurrent inflammation 
(13). 
No previous paper focused on the assessment of malnutrition as defined by 
the latest ESPEN consensus. The present study identified a 20.4% prevalence 
of malnutrition, demonstrating an association between the presence of 
malnutrition and GOLD stages. In fact, 83% of malnourished patients suffer 
from severe or very severe disease (GOLD stage III or IV) and, considering only 
malnourished patients with inflammation, the percentage of those with the most 
advanced disease stage increases to 95%. 
Beyond some obvious differences between non-malnourished vs 
malnourished patients, the two groups of malnourished patients (with and 
without inflammation) do not differ from each other in terms of a number of 
nutritional variables, such as BMI, FFM and ASM estimates, suggesting that 
the greatest differences were between malnourished vs non malnourished 
patients. 
However, beyond body composition estimates, the use of raw variables 
generated by a BIA device, such as PhA or IR, could have utility independently 
of body composition estimates, as markers of extracellular/intracellular 
distribution of water, body cell mass and muscle quality (39-45). In this 
perspective, we aimed to compare raw BIA data among patients with different 
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grades of malnutrition in order to find out whether these variables could 
contribute to further phenotype these patients.  
 No studies have previously examined the relationship between diagnosis 
of malnutrition and raw BIA data in COPD. This study shows a clear worsening 
of raw BIA data in malnourished patients with inflammation, compared to non-
malnourished and, within the group of malnourished patients, in those with 
inflammation. This is probably due to the effect of the chronic low-grade 
inflammation on muscle quality (46-48).   
Sarcopenia is another recognized extra-pulmonary manifestation of COPD, 
being related to contributing factors, including physical inactivity, malnutrition 
and chronic disease.  
Several definitions of sarcopenia have been previously proposed, some of 
those only consider low muscle mass, as suggested by the recent European 
Respiratory Society (ERS) statement for nutritional assessment and therapy (2). 
However, the current international consensus developed by the EWGSOP (and 
endorsed by ESPEN) is that the sarcopenia syndrome includes the presence of 
both low muscle mass and function (i.e. strength and performance) (6, 10, 13). 
Only few papers have examined sarcopenia in COPD using EWGSOP 
criteria. Jones et al. (49) have recently found out a prevalence of 14.5% of 
sarcopenia among stable COPD patients, which increased with age and disease 
severity (49).  
According to the present study, the overall prevalence of sarcopenia is 
25.0%, being higher across GOLD stages. Indeed, 90% of sarcopenic patients 
are in GOLD stages III or IV, with a percentage that remain stable for those with 
moderate or severe sarcopenia, separately. 
With respect to nutritional variables, BMI and estimates of FFM and ASM 
are reduced in severe sarcopenic patients. However, of these three variables, 
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only BMI has been found to be reduced also in moderate sarcopenia, compared 
to non-sarcopenic patients. 
Similarly to what described in malnourished patients, the present study showed 
some differences between grades of sarcopenia. These differences were 
particularly marked with respect of HGS and raw BIA variables (IR and PhA). 
Finally, the present study pointed out some discrepancies between 
prevalence of malnutrition and sarcopenia. In fact, 42.4% of sarcopenic patients 
do not fulfil the ESPEN criteria of malnutrition, while 28.3% of malnourished 
patients do not fulfil the EWGSOP criteria of sarcopenia.  
We acknowledge argument around the use of BIA for the assessment of 
muscle mass, as compared with reference methods, such as dual-energy X-ray 
absorptiometry (DEXA) or MRI. Nevertheless, BIA offers a simple, portable 
and non invasive method for the assessment of muscle mass that was considered 
acceptable by the EWGSOP. 
Defining nutritional disorders and nutrition-related conditions in COPD 
should be of primary importance in future studies. According to the preliminary 
results of the present study, there is an urgent need of using standardized and 
reproducible criteria for diagnosing malnutrition and sarcopenia in COPD. As a 
matter of fact, the use of ESPEN criteria provide an valuable approach for 
differencing cachectic and non-cachectic patients. In fact, withing the group of 
malnourished patients, several differences emerge between patients with and 
without inflammation, especially with respect to IR and PhA. In particular, the 
most evident BIA alterations emerge in malnourished patients with 
inflammation. Further research should also analyse whether malnutrition and/or 
sarcopenia are predictive factors for clinical outcomes in these patients. 
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5. Tables 
Table 1: General characteristics, body composition, BIA variables and HGS in COPD patients 
across stages of malnutrition. 
 
No 
malnutrition 
Malnutrition 
without 
inflammation 
Malnutrition 
with 
inflammation 
 (N. 207) (N. 33) (N.20) 
Age (years) 69.9±7.9 69.9±7.9 69.1±8.8 
Males/females (number) 142/65 23/10 18/2 
Patients GOLD III-IV (number) 136 (65.7%) 25 (75.8%) 19 (95.0%) 
Height (cm) 160.5±9.2 160.3±7.4 163.1±9.0 
Weight (kg 72.1±14.1ab 48.9±6.6a 47.2±7.6b 
BMI (kg/m2) 28.0±4.8ab 18.9±1.7a 17.8±2.2b 
FEV1 (% pred.) 43.8±18.2b 38.1±21.7 29.6±12.3b 
IC/TLC 0.23±0.09ab 0.18±0.07a 0.15±0.05b 
HGS (kg) 25.1±5.6b 23.4±6.3 20.3±7.2b 
Low HGS (number) 126 (60.9 %) 24 (72.7 %) 14 (70.0 %) 
FFM (kg) 48.2±5.7ab 39.2±4.2a 37.6±4.3b 
Low FFMI (number) 13 (6.3 %) 33 (100%) 20 (100%) 
FM (kg) 24.1±9.2ab 9.8±4.8a 7.4±5.3b 
ASM (kg) 22.7±3.0ab 18.4±2.7a 16.9±2.4b 
Low ASMI (number) 29 (14.0 %) 23 (69.7%) 18 (90.0%) 
250/5 kHz impedance ratio 0.814±0.027b 0.817±0.026c 0.838±0.031bc 
100/5 kHz impedance ratio 0.869±0.022b 0.876±0.024c 0.892±0.025bc 
50/5 kHz impedance ratio 0.909±0.018b 0.915±0.018 0.926±0.022b 
Phase angle (degrees) 4.88±0.80b 4.63±0.94 4.15±0.88b 
Note:  Data are presented as mean values ± standard deviation or count data and percentage. FFM, 
ASM, impedance ratios (250/5, 100/5 and 50/5 IR), phase angle, and HGS data adjusted for gender 
and age. a or b or c = p<0.05 between the two groups 
Abbreviations: GOLD, global initiative for chronic obstructive lung disease; BMI, body mass 
index; FEV1, forced expiratory volume in 1 second; IC/TLC, inspiratory capacity/ total lung 
capacity; HGS, handgrip strength; FFM, fat-free mass; FFMI, FFM index; ASM, appendicular 
skeletal muscle mass; ASMI, ASM index. 
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Table 2: General characteristics, body composition, BIA variables and HGS in COPD patients 
across stages of sarcopenia 
 
No sarcopenia 
Moderate 
sarcopenia 
Severe sarcopenia 
 (N. 194) (N. 22) (N.44) 
Age (years) 69.6±7.9 68.4±8.8        71.3±7.5 
Males/females (number) 123/71 19/3 41/3 
Patients GOLD III-IV (number) 120 (61.9 %) 20 (90.9%) 40 (90.9%) 
Height (cm) 159.5±9.0ab 165.9±7.7a      163.3±8.4b 
Weight (kg    70.9±15.5ab 59.1±11.5a  55.2±13.7b 
BMI (kg/m2)  27.8±5.3ab 21.4±3.3a         20.7±4.2b 
FEV1 (% pred.)   45.7±18.4ab 32.3±12.7a  30.4±16.0b 
IC/TLC 0.023±0.09ab 0.018±0.08a 0.016±0.06b 
HGS (kg) 25.7±5.5b 24.9±4.4c         19.1±5.5bc 
Low HGS (number) 110 (56.7 %) 10 (45.5 %) 44 (100 %) 
FFM (kg) 48.0±6.0b 42.4±4.9 40.0±5.9b 
Low FFMI (number) 19 (9.8 %) 15 (68.2 %) 32 (72.7 %) 
FM (kg) 23.6±9.9ab 14.9±7.7a 12.5±8.5b 
ASM (kg) 22.9±3.0ab 18.8±2.2a 17.7±2.6b 
Low ASMI (number) 4 (2.1 %) 22 (100 %) 44 (100 %) 
250/5 impedance ratio  0.813±0.027b 0.813±0.028c   0.831±0.028bc 
100/5 impedance ratio  0.869±0.022b 0.871±0.023c    0.888±0.023bc 
50/5 impedance ratio   0.908±0.018b 0.911±0.019c    0.923±0.018bc 
Phase angle (degrees)   4.91±0.80b 4.76±0.94   4.29±0.84b 
Note:  Data are presented as mean values ± standard deviation or count data and percentage. FFM, ASM, 
impedance ratios (250/5, 100/5 and 50/5 IR), phase angle, and HGS data adjusted for gender and age. a 
or b or c = p<0.05 between the two groups 
Abbreviations:   GOLD, global initiative for chronic obstructive lung disease; BMI, body mass index; 
FEV1, forced expiratory volume in 1 second; IC/TLC, inspiratory capacity/ total lung capacity; HGS, 
handgrip strength; FFM, fat-free mass; FFMI, FFM index; ASM, appendicular skeletal muscle mass; 
ASMI, ASM index. 
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Table 3. Cross tabulation data of patients with and without malnutrition and/or sarcopenia  
 
 
No Malnutrition 
 
Malnutrition 
without 
inflammation 
(non-cachectic) 
Malnutrition 
with 
inflammation 
(cachectic) 
Total 
No sarcopenia  179 12 3 194 
Moderate/severe 
sarcopenia 
 
28 21 17 66 
Total 207 33 20 260 
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Table 4: General characteristics, body composition, BIA variables and HGS in malnourished 
COPD patients with and without sarcopenia 
Note: Data are presented as mean values ± standard deviation or count data. FFM, FFMI, FM, FMI, 
ASM, ASMI, IR, PhA and HGS adjusted for gender and age. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; IC/TLC, 
inspiratory capacity/ total lung capacity; , GOLD, global initiative for chronic obstructive lung disease; 
FFM, fat-free mass; FFMI, FFM index; ASM, appendicular skeletal muscle mass; ASMI, ASM index. 
 
Malnourished 
without sarcopenia 
Malnourished 
with sarcopenia 
P values 
 (N. 15) (N. 38)  
Age (years) 68.9±8.2    69.9±8.2   0.682 
Males/females (number) 5/10         36/2 <0.001 
Patients GOLD III-IV (number) 9 (60.0 %) 35 (92.1 %)   0.005 
Height (cm) 157.7±8.5   162.8±7.4   0.036 
Weight (kg 48.8±5.5     48.1±7.5   0.764 
BMI (kg/m2) 19.5±1.5     18.1±2.0   0.023 
FEV1 (% pred.)  50.5±24.4     28.7±12.1 <0.001 
IC/TLC  0.20±0.07     0.15±0.05   0.004 
HGS (kg) 26.9±6.3 20.4±6.0   0.001 
Low HGS (number) 6 (40.0 %) 32 (84.2 %)   0.001 
FFM (kg) 41.2±3.6      37.6±4.1   0.004 
Low FFMI (number) 15 (100 %) 38 (100 %) <0.001 
FM (kg) 8.9±2.9        9.5±4.1   0.589 
ASM (kg)          20.3±2.1      16.9±2.2 <0.001 
Low ASMI (number) 3 (20.0 %) 38 (100 %) <0.001 
250/5 impedance ratio 0.816±0.030 0.828±0.028   0.180 
100/5 impedance ratio 0.871±0.024 0.887±0.025   0.050 
50/5 impedance ratio 0.911±0.018  0.922±0.020           0.075 
Phase angle (degrees) 4.84±0.89  4.30±0.92   0.060 
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Note: Data are presented as mean values ± standard deviation, percentage or count data. FFM, FFMI,  
FM, ASM, ASMI, impedance ratio, phase angle and handgrip strength adjusted for gender and 
age.Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; IC/TLC, 
inspiratory capacity/ total lung capacity; HGS, handgrip strength FFM, fat-free mass; FFMI, FFM 
index; ASM, appendicular skeletal muscle mass; ASMI, ASM index. 
 
 
 High IR and low PhA 
(n.33) 
Other patients 
(n.147) 
 
P value 
Age (years) 72.8±7.2 67.9±7.8   0.001 
Height (cm) 158.9±9.2 162.8±7.8   0.012 
Weight (kg) 57.8±15.4 67.2±15.5   0.002 
BMI 23.0±5.9 25.3±5.2   0.026 
FEV1 (% pred.) 34.8±15.4 31.8±10.1   0.180 
IC/TLC 0.17±0.07 0.20±0.10   0.230 
HGS (kg) 19.1±6.6 27.3±7.4 <0.001 
FFM (kg) 42.2±6.9 47.2±8.1   0.001 
Low FFMI (number) 15 40   0.035 
FM (kg) 15.6±11.3 20.1±9.7   0.022 
ASM (kg) 19.7±4.3 22.5±4.9   0.003 
Low ASMI (number) 16 46   0.049 
250/5 impedance ratio 0.859±0.018 0.809±0.023 <0.001 
Phase angle 3.47±0.50 4.98±0.680 <0.001 
Prevalence of malnutrition (%) 39.4% 21.1%   0.027 
Prevalence of sarcopenia (%) 48.5% 29.9%   0.041 
 Table 5.  Respiratory function, body composition and muscle strength in 180 selected 
COPD patients with GOLD III and IV, divided into quartiles, according to IR and PhA 
values 
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Abstract 
Multifrequency bioelectrical impedance analysis (MF-BIA) is a technique 
that measures body impedance (Z) at different frequencies (5, 10, 50, 100, and 
250 kHz). Body composition may be estimated using empirical equations, 
which include BIA variables or, alternatively, raw BIA data may provide direct 
information on water distribution and muscle quality. 
The aim of this study was to compare raw MF-BIA data between COPD 
patients and controls and to study their relationship with respiratory and 
functional parameters in COPD patients. 
MF-BIA was performed (Human Im-Touch analyzer) in 212 COPD patients 
and 115 age- and BMI-matched controls. Fat-free mass (FFM) and fat mass 
were estimated from BIA data, and low- to high-frequency (5 kHz/250 kHz) 
impedance ratio was calculated. Physical fitness, lung function and respiratory 
muscle strength were also assessed in COPD patients. 
After adjusting for age, weight, and body mass index, FFM and the 5/250 
impedance ratio were lower in COPD patients (P0.001) and were negatively 
affected by disease severity. In both male and female patients, the 5/250 
impedance ratio was significantly correlated mainly with age (r=-0.316 and r=-
0.346, respectively). Patients with a 5/250 impedance ratio below median value 
had lower handgrip strength (P<0.001), 6-minute walk distance (P<0.005), 
respiratory muscle strength (P<0.005), forced expiratory volume in 1 second 
(P<0.05) and vital capacity (P<0.005). Finally, the 5/250 impedance ratio was 
reduced (P<0.05) in patients with Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) III and IV (compared to those with GOLD I and II) or a 
BODE index between 6 and 10 points (compared to those with BODE index 
between 1 and 5 points). 
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In conclusion, MF-BIA may be a useful tool for assessing body composition 
and nutritional status in COPD patients. In particular, the impedance ratio could 
give valuable information on cellular integrity and muscle quality.  
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1 Introduction and aims 
Nutrition and the evaluation of body composition play an increasingly central 
role in the diagnosis, assessment and management of COPD. Besides smoking 
cessation, pharmacological therapies and management of comorbidities, Celli 
et al. (1) have recently indicated nutritional assessment to be one of the most 
important topics in COPD. 
Several techniques are available to assess body composition in COPD, 
including anthropometry, bioelectrical impedance analysis (BIA), dual-energy 
X-ray absorptiometry (DXA) as well as more advanced imaging technologies 
like computed tomography (CT), high-resolution computed tomography 
(HRCT) and magnetic resonance imaging (MRI) (2). The choice of method 
depends not only on the type of study and the number of compartments to be 
studied, but also on its applicability in clinical practice (3). 
Bioelectrical impedance analysis (BIA) is the bedside method that has been 
most widely investigated in clinical research, due to its affordability, portability, 
and ease of use (4). Actually, BIA does not directly measure body composition; 
estimates of body composition are derived from raw BIA data, such as 
impedance (Z), resistance, reactance and phase angle, using predictive 
equations (5). Alternatively, information about water distribution (between 
intra- and extra-cellular compartments) and cell integrity may be obtained 
through the electrical properties of body compartments from raw data, such as 
low to high frequency impedance ratio and phase angle (6-9). 
BIA can be applied for estimating body composition  using data generated 
by single-frequency BIA (SF-BIA), multifrequency BIA (MF-BIA) or 
bioimpedance spectroscopy (BIS) devices (5, 10).  
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1.1 Single frequency BIA  
SF-BIA devices measure impedance variables (i.e, Z, and PhA) at a single 
frequency, typically 50 kHz. 
SF-BIA is useful to estimate a body compartment (i.e. total body water, 
TBW and FFM) in patients with COPD, using several disease-specific 
predictive equations (11-14), which include BIA variables. However, general 
predictive equations and manufacturer's equations have also been frequently 
used. The choice of a prediction equation (from the abundant literature on the 
topic) that ideally matches the patient that he or she wishes to assess, is one of 
several limitations to the application of SF-BIA in the clinical setting (10).  
Alternatively, as suggested by a growing number of authors(5, 10), a 
potentially useful approach to the use of SF-BIA might be to use the raw data 
generated, in particular, PhA. 
Very few data have been published on SF-BIA raw data in COPD, 
specifically focusing on PhA (15-17). As reported by previous papers, it was 
shown to be higher in males, negatively correlated with age and positively with 
BMI and FEV1 (% predicted) (15). Furthermore, it was shown to be 
significantly decreased across COPD stages suggesting that lower PhA may be 
associated with decreased cell integrity (16).  
1.2 Multifrequency BIA 
MF-BIA devices measure Z at several frequencies, usually in the range between 
1-1000 kHz (5). Since at low frequency the current cannot pass through the cell 
membrane due to its capacitance, low frequency currents are conducted only 
through extra-cellular water (ECW), whereas high frequency currents penetrate 
cell membranes and are thus used to estimate total body water (TBW) (18). As 
a consequence, low to high frequency impedance ratio (i.e Z at 5 kHz / Z at 250 
kHz) is a derived MF-BIA variable which provides information on water 
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distribution between intra and extra-cellular compartments and therefore on 
body cell mass and muscle quality (6, 9, 19).  
In patients with COPD, BIA has usually been used to estimate FFM and 
body composition through predictive equations. As previously stated, very few 
studies had focused on raw BIA data in patients with COPD, specifically 
focusing on SF-BIA data (i.e PhA) and no comparison with healthy subjects has 
been carried out yet. Furthermore, no data on low to high frequency impedance 
ratio are available in COPD patients.   
The general aim of this study was to evaluate whether MF-BIA is a useful 
tool for the assessment of nutritional status in COPD patients. More specifically, 
this study compared MF-BIA between COPD patients and matched controls and 
investigated the association of MF-BIA with gender, age, weight, BMI and FFM 
in COPD patients. Also, the relationship of MF-BIA with established markers 
of physical fitness, lung function and respiratory muscle strength in COPD 
patients was studied. 
2. Methods 
2.1 Subjects 
Two hundred and sixty patients with COPD, consecutively admitted to the 
Pulmonary Rehabilitation Section of Clinic Center S.p.A (Naples, Italy) from 
March 2013 to November 2015, were assessed for eligibility. Forty-eight COPD 
patients did not meet the general inclusion criteria. Furthermore, a group of age 
and BMI matched controls, from a larger database was included. Inclusion 
criteria for both groups were age >50 years and BMI between 20 and 35 kg/m2. 
For COPD patients a baseline post-bronchodilator Forced Expiratory Volume 
in 1 second (FEV1)⁄forced vital capacity (FVC) of <70 was mandatory to be 
enrolled. Exclusion criteria were related to diagnosis of known respiratory 
disorders other than COPD, known history of significant inflammatory disease 
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other than COPD, a COPD exacerbation within 4 weeks of enrolment, and long 
term (>3 consecutive months) oral corticosteroids at time of inclusion. In 
addition, the usual criteria of uncontrolled disease (i.e. peripheral oedema or 
instable heart failure) likely to interfere with the study or impact on subject 
safety and substance abuse were applied.  
Ethical approval was not indicated because all of the tests were done as part 
of the routine initial assessment, and analyzed retrospectively. De-identified 
records were used for COPD patients.. The Ethics Committee of Federico II, 
University of Naples, approved the study protocol for controls. 
2.2 Study protocol 
Starting at 9.30 AM, COPD patients and control subjects underwent body 
composition assessment. The same nutritionist always collected all data.  For 
COPD patients, respiratory and other clinical parameters measurements 
followed, under the supervision of a chest physician. Always for COPD 
patients, physical fitness tests were also carried out. 
2.3 Body composition 
Body height and weight were measured using a platform balance (SECA 
711+220; Hamburg - Germany), and body mass index (BMI) was calculated as 
body weight⁄height2. Body composition was assessed by performing MF-BIA 
in standardized conditions (i.e. ambient temperature between 23 and 25°C,  fast 
of > 3 h, empty bladder, clean skin surface), using a Human Im-Touch analyzer 
(© DS Medica S.r.l., Milan, Italy). 
Participants were asked to remain in the supine position for at least 10 
minutes before starting the measurement, with legs and arms slightly abducted 
at 30° so there was no contact between the extremities and trunk.  
   CHAPTER V 
129 
 
Briefly, the procedure involves the placement of 2 electrodes on the hand 
(one on the bony protuberance that forms the wrist, i.e. the styloid process of 
the ulna, and the other just behind the meta-carpals), and 2 electrodes on the 
foot (one on the ankle placed midline between the medial and lateral malleoli, 
i.e. the styloid process of the radius, and the other just behind the metatarsals). 
The procedure was repeated for the left side.  
Z was determined at five frequencies (5 kHz, 10 kHz, 50 kHz, 100 kHz and 
250 kHz) with an imperceptible electrical current of 800 mA. In addition, 
bioelectrical impedance index (BI index) and low-to high- frequency impedance 
ratio were obtained as explained below. BI index was calculated by squared 
height divided by impedance at 50 kHz representing an established parameter 
of TBW (20). Z at 5 kHz and Z at 250 kHz are thought to be inversely related 
to ECW and TBW, respectively. By considering TBW as the sum of ECW+ 
intra-cellular water (ICW), for the same ECW, an increase of TBW may be 
interpreted as an increase in ICW. Therefore, as suggested by previous papers 
(5, 10), the ratio between Z at 5 kHz to Z at 250 kHz (5/250 impedance ratio) is 
used as an indicator of fluid distribution between intra/extra cellular 
compartments and muscle quality (10). FFM and FFM index (FFMI kg/m2 = 
FFM/height2) were estimated from Z at 50 kHz using a validated predictive BIA 
equation (21) in both groups for consistency, and also a disease specific 
equation in COPD patients only (14). FM and FMI (FMI kg/m2 = FM/height2) 
were calculated as total body weight minus FFM.  
2.4 Lung function  
All COPD patients performed a baseline post-bronchodilator spirometry 
and body plethysmography (QBOX® COSMED) according to ATS/ERS 
standardization (22). FEV1 and FVC were assessed in accordance with the latest 
GOLD guidelines (23). Vital capacity (VC) and inspiratory capacity (IC) were 
assessed too. Plethysmographic lung volumes, such as Total Lung Capacity 
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(TLC), Intra Thoracic Gas Volume (ITGV) and Residual Volume (RV) were 
assessed. IC/TLC ratio (24) was calculated by dividing TLC−ITGV for TLC, 
and was used as a marker for hyperinflation, the abnormal increase in the 
volume of air remaining in the lungs at the end of spontaneous expiration (25). 
2.5 Respiratory muscle strength  
Maximum inspiratory pressures (MIP) and maximum expiratory pressures 
(MEP) were measured according to the method described by Black and Hyatt 
(26). Measurements were obtained in the sitting position with MicroRPM® 
(CareFusion, Hoechberg, Germany). 
2.6 Physical fitness  
As measures of physical fitness, handgrip strength (HGS) and 6-minute walk 
test (6MWT) were performed. 
HGS, a surrogate measurement of overall muscle strength (27), was 
measured at baseline with a digital dynamometer (Dynex, MD systems Inc 
.Ohio USA). Three measurements were taken for both body sides. The 
maximum values obtained for each side was considered for statistical analysis 
(28). 
6MWT was performed according to ATS standards (29), during which 
oximetry was performed at 10-second intervals with a pulse oximeter 
(Nellcor™ OxiMax N-65; Covidien, Boulder, CO). The 6-minute walk distance 
(6MWD) was the primary outcome of the 6MWT. 
2.7 Other measurements 
Breathlessness was measured by using the Medical Research Council (MRC) 
dyspnoea scale (30). A composite prognostic index, the BODE index (31), was 
used as surrogate of global disease severity. 
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2.8 Statistical analyses 
Values were reported as means ± standard deviation (SD) unless otherwise 
specified. Comparisons between COPD patients and controls were conducted 
by analysis of variance (ANOVA). A general linear model (GLM) was applied 
for adjusting for age, weight and BMI. Additional analyses were performed in 
the COPD patients. Correlations were performed between 5/250 impedance 
ratio and weight, BMI, FFM and FFMI. In order to evaluate the impact of 5/250 
ratio on physical fitness and respiratory parameters in COPD, male and female 
patients were also stratified according to the median value of 5/250 impedance 
ratio (124.4 for males; 122.7 for females). Subsequently, GLM was performed 
to investigate the association of the 5/250 impedance ratio with COPD diagnosis 
and severity. Statistical analysis was performed using SPSS version 20.0 and a 
p value <0,05 was considered significant in all analyses. 
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3 Results 
3.1 Participants 
After excluding 48 COPD patients who did not satisfied inclusion and exclusion 
criteria, 212 patients with stable COPD (144 men and 68 women) and 115 age-
and-BMI matched controls (53 men and 62 women) were enrolled in this study. 
Age and BMI were comparable between COPD patients and controls, while a 
small difference in terms of weight still existed (table 1). 
Participants had a mean age of 69.9±7.6 and 68.6±7.4 years and a mean 
BMI of 26.4±4.1 and 27.2±2.5 kg/m2 (COPD and controls, respectively). 
Within the COPD group, patients had a mean FEV1% predicted of 45.3% and 
COPD severity ranged from mild to very severe (GOLD I/II/III/IV:  
2.5/30.8/37.3/29.4%).  
3.2 Body composition in COPD patients compared to controls 
In the unadjusted model, both male and female COPD patients had reduced 
FFM and FFMI compared to controls, while no difference was seen in FM or 
FMI. After adjusting for age, weight and BMI, FFM remained significantly 
reduced (and FM became significantly higher) in COPD patients compared to 
controls (between-group difference 2.33 kg; p<0.001).  
With respect to raw MF-BIA data, the 5/250 impedance ratio was found to 
be significantly lower in COPD patients compared to controls both in males 
(124.1±4.9 vs 126.8±4.7; p<0.001) and females (122.3±4.1 vs 126.0±3.5; 
p<0.001), even after adjusting for age, weight and BMI (p<0.001).  
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3.3 Impedance ratio in COPD patients 
Determinants of 5/250 impedance ratio in COPD 
The 5/250 impedance ratio was higher (p <0.001) in male patients compared to 
female patients. The 5/250 impedance ratio was inversely related to age, both 
in males (r= −0.316; p<0.001) and females (r= −0.346; p<0.005).  A significant 
correlation with weight (r=0.261; p<0.001), BMI (r=0.264; p<0.001), FFM 
(r=0.287; p<0.001) and FFMI (r=0.286; p<0.001) emerged only in males.  
Body composition and clinical characteristics in patients with a low 5/250 
impedance ratio 
In table 2, COPD patients were stratified according to the median value of the 
5/250 impedance ratio. In men, but not in women, lower values of 5/250 
impedance ratio were associated with lower BMI (p<0.01), FFMI (p<0.02) and 
FMI (p<0.05). In addition, a significant reduction in HGS (and 6MWD) was 
seen both in male patients (p<0.001) and female patients (p<0.001). The same 
was true for 6MWD (see table 2). All these differences persisted after adjusting 
for age, weight and BMI. HGS (and 6MWD) was more strongly related to the 
5/250 impedance ratio than to FFM or FFMI, both in male patients (r=0.514 vs 
r=0.399 and vs r=0.251; respectively) and female patients (r=0.660 vs r=0.204 
and vs r=-0.204 respectively). 
Table 3 shows respiratory parameters of COPD patients stratified according 
to the median value of the 5/250 impedance ratio. Patients with lower values 
had significantly lower FEV1 (p=0.049) and VC (p=0.005), while no difference 
was found in any of the static lung hyperinflation markers considered (RV, 
ITGV, IC/TLC).  
Regarding respiratory muscle strength, both MIP (p<0.001) and MEP 
(p=0.001) were significantly reduced in patients with lower 5/250 impedance 
ratio. Actually, MIP and MEP were more strongly related to 5/250 ratio 
   CHAPTER V 
134 
 
(r=0.471 and r=0.411 respectively) (figure 1a and 1b) than to FFM (r=0.352 and 
r=0.346) or FFMI (r=0.344 and r=0.306). 
Finally, after adjusting for age, weight and BMI, the 5/250 impedance ratio 
was significantly reduced (p<0.05) in patients with GOLD III and IV, compared 
to those with GOLD I and II. Likewise, lower 5/250 impedance ratio (p<0.001) 
was reported in male as well as female patients with a BODE index between 6-
10 points compared to those with an index between 1-5 points, even after 
adjusting for age, weight and BMI (p<0.001). 
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4. Discussion 
The present study indicates that MF-BIA is a valid tool for identifying COPD 
with poor nutritional status. In particular, the 5/250 impedance ratio was 
decreased in COPD patients and relates to function and disease severity.  
Alteration in nutritional status, which is a systemic effect of COPD, may be 
assessed using different methods. In particular, BIA is a widely used bedside 
method, to obtain estimates of body composition (TBW and FFM) using 
predictive equations (32, 33). In the present study, for consistency we used the 
same formula (21) to estimate FFM and FM in both COPD patients and controls. 
In accordance with previous papers (34-36), our study shows that FFM is 
significantly lower in COPD patients compared to controls. More interestingly, 
this difference persisted after adjusting for age, weight and BMI. In other words, 
COPD patients exhibited a lower ratio between lean tissues and adipose tissue, 
which is a typical feature of sarcopenia (37). Similar findings were obtained 
when a disease specific equation for COPD patients was employed (14).  
Another issue of increasing interest is how to evaluate body composition in 
the clinical setting using raw BIA variables. In this regards, very few data are 
so far available for COPD patients; in particular, phase angle, as an index of cell 
quantity and/or cellular health, was recently shown to be independently 
associated with measures of physical fitness and disease severity (15, 38). On 
the other hand, to the best of our knowledge, there are no data on MF-BIA in 
COPD patients. MF-BIA measures Z at several frequencies: at low frequency, 
current is conducted only through ECW, whereas at high frequency it can 
penetrate cell membranes, being associated with TBW (18). Consequently, low 
to high frequency impedance ratios are raw MF-BIA derived variables that may 
provide direct information on both water distribution between intra-cellular and 
extra-cellular compartments and muscle quality (6, 9, 19). 
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To the best of our knowledge, this is the first study that compared the 
impedance ratio between COPD and controls. Our results show that the 5/250 
impedance ratio is reduced in COPD patients compared to age-and-BMI 
matched controls (independently of age, weight and BMI) suggesting the 
presence of a disease-related cellular deterioration.  
As far as between-patients variability was considered, age emerged as the 
most powerful predictor of the 5/250 impedance ratio in both genders, while 
after adjusting for age, no relationship persisted with weight, BMI or FFM (data 
not shown). These results were in line with previous papers showing that phase 
angle significantly declined with age in COPD patients (15). 
From a clinical point of view, evaluating the relationship between body 
composition and body functions is a major issue in the diagnosis, assessment 
and management of chronic diseases. When COPD patients were stratified 
according to the median value of the 5/250 impedance ratio, those with a lower 
5/250 impedance ratio exhibited poorer physical fitness, as estimated by HGS 
and 6MWD. Even more interestingly, in both genders, HGS, 6MWD and 
respiratory muscle strength (MIP and MEP) were more strongly related to the 
5/250 impedance ratio than to FFM or FFMI. Furthermore, reduced lung 
function (ie FEV1 and VC) was also seen in patients with a 5/250 impedance 
ratio below median value.  
Finally, the reduction of the 5/250 impedance ratio was more pronounced 
in GOLD stages III/IV compared to I/II, even when age and BMI were taken 
into account as covariates. Likewise, a reduction of the 5/250 impedance ratio 
was observed in the patients with a higher BODE index (6-10 vs 1-5 BODE 
score). Thus, differences in the impedance ratio were related to disease severity. 
4.1 Strength and limitations of the study 
Taking into account that the experimental protocol was carried out in a single 
centre and had cross sectional study design, to the best of authors’ knowledge, 
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this is the first study that evaluates impedance ratio. In addition, a quite large 
sample of COPD patients, with different disease severity and function 
impairment was studied. The main limitation is related to the fact that FFM was 
not concurrently measured with a reference technique, such as DXA. However, 
DXA does not provide information on water distribution between intra-cellular 
and extra-cellular compartments or muscle quality. 
Overall, the results of the present study indicate that FFM and the 
impedance ratio were decreased in COPD patients, even after adjusting for age, 
weight, and BMI. The impedance ratio is affected by clinical conditions, being 
related to physical fitness and lung function. Thus, MF-BIA may be a useful 
tool for assessing body composition and nutritional status in COPD patients, 
especially with respect to cellular integrity and muscle quality. 
5. Conclusion 
Nutritional status is an important determinant of outcome of COPD. The 
measurement of raw MF-BIA data could be useful as a bedside approach, 
independently of body composition estimates, by allowing clinicians to identify 
malnourished patients, even if they are not underweight. Further multicentre 
studies are needed to better define the role of MF-BIA in assessing changes in 
nutritional status with time, due to clinical status, rehabilitation and nutritional 
treatment. 
  
   CHAPTER V 
138 
 
Table 1: Age and body composition parameters of 212 COPD patients and 115 
age-and-BMI matched controls. 
 Males 
(N=197) 
Females 
(N=130) 
 COPD 
(N=144) 
Controls 
(N=53) 
p 
Value 
COPD         
(N=68) 
Controls 
(N=62) 
p 
Value 
Age (years) 70.3±7.3 68.5±7.8 0.117 69.1±8.2 68.7±7.0 0.752 
Height 
(cm) 
165.4±7.0 167.5±6.9 0.063 152.3±6.4 156.9±7.5 <0.001 
Weight 
(kg) 
71.4±12.6 75.3±9.3 0.041 62.7±10.7 68.0±8.4 0.002 
BMI 
(kg/m2) 
26.0±3.9 26.7±2.4 0.227 27.0±4.6 27.6±2.7 0.383 
FFM (kg) 53.0±7.2 57.6±7.4 <0.001 40.3±3.6 45.3±5.5 <0.001 
FFMI 
(kg/m2) 
19.3±1.4 20.5±1.7 <0.001 17.4±1.3 18.3±1.3 <0.001 
FM (kg) 18.4±7.2 17.7±5.3 0.552 22.4±7.8 22.8±5.4 0.780 
FMI 
(kg/m2) 
6.7±2.5 6.3±1.9 0.330 9.7±3.3 9.3±2.1 0.373 
5/250 IR  124.1±4.9 126.8±4.7 <0.001 122.3±4.1 126.0±3.5 <0.001 
Note: Mean value ± standard deviation.  
Abbreviations: BMI, Body Mass Index; FFM, Fat-Free Mass; FFMI, Fat-Free Mass Index; FM, Fat 
Mass; FMI, Fat Mass Index; 5/250 IR,  ratio between impedance at 5kHz and 250 kHz. 
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Table 2: General characteristics of 212 COPD patients divided by gender and 
stratified according to the median value of 5/250 impedance ratio (124.4 for 
men; 122.7 for women).  
 
  COPD male patients 
(N=144) 
COPD female patients  
(N=68) 
 5/250 IR 
Below median 
value 
 (n.72) 
5/250 IR 
Above median 
value 
 (n.72) 
p Value* 5/250 IR 
Below median 
value 
 (n.34) 
5/250 IR 
Above median 
value 
 (n.34) 
p Value* 
Age (years) 71.7±7.6 69.0±6.8 0.029 71.3±8.2 67.1±7.6 0.030 
Weight (kg) 68.7±14.6 74.0±13.3 0.012 61.7±17.4 64.5±10.1 0.269 
BMI (kg/m2) 25.2±3.8 26.9±3.9 0.009 26.4±4.0 27.6±4.7 0.246 
FFMI 19.0±2.0 19.7±1.9 0.018 17.4±2.4 17.5±1.4 0.719 
FMI 6.3±2.5 7.1±2.2 0.045 10.2±6.9 10.1±3.4 0.979 
HGS (Kg) 25.7±5.7 33.0±7.0 <0.001 16.1±3.3 22.0±4.9 <0.001 
6MWD (m) 0; 348 300; 434 0.002 0; 60 240; 349 0.030 
Note: Mean value ± standard deviation. Median value and interquartile range for 6MWD.  
Abbreviations: 5/250 IR, ratio between impedance at 5kHz and 250kHz; BMI, Body Mass Index; FFMI, Fat-Free Mass 
Index; FMI, Fat Mass Index; HGS, handgrip strength – dominant side; 6MWD, 6 Minute Walk Distance. 
 
 
  
   CHAPTER V 
140 
 
Table 3: Respiratory parameters of 212 COPD patients stratified according to 
the median value of 5/250 impedance ratio (124.4 for men; 122.7 for women). 
 COPD patients (N=212) 
 5/250 
Below median 
value 
(n.106) 
5/250 
Above median 
value 
 (n.106) 
p Value* 
FEV1  (% predicted) 42.52±18.3 47.7±19.3 0.049 
VC (% predicted) 66.0±17.8 73.3±19.0 0.005 
RV (% predicted) 243.1±66.7 258.9±68.6 0.093 
ITGV  (% predicted) 183.3±49.1 195.1±48.9 0.081 
IC/TLC 0.3±0.8 0.2±0.3 0.498 
MIP (cmH2O) 49.9.5±17.7 61.7±20.8 <0.001 
MEP (cmH2O) 72.2±24.2 84.5±27.3 0.001 
MRC dyspnoea scale 3.8±0.4 3.6±0.5 0.037 
Note: Mean value ± standard deviation.  
Abbreviations: 5/250: impedance ratio between Z at 5kHz and Z at 250 kHz.; FEV1: Forced Espiratory Volume in 1° 
Second; FVC: Forced Vital Capacity; VC: Vital Capacity; RV: Residual Volume; ITGV: Intrathoracic gas volume; IC: 
Inspiratory Capacity; TLC: Total Lung Capacity; MIP: Maximal Inspiratory Pressure; MEP: Maximal Espiratory 
Pressure 
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Figure 1. Correlation plot of MIP with 5/250 impedance ratio in 212 COPD 
patients (r = 0.471; p<0.001) 
 
 
 
MIP 
5/
25
0 
im
p
ed
an
ce
 r
at
io
 
   CHAPTER V 
142 
 
Figure 2. Correlation plot of MEP with 5/250 impedance ratio in 212 COPD 
patients (r = 0.411; p<0.001) 
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Abstract 
Loss of fat free mass (FFM) and reduced muscle strength, which are both highly 
prevalent in chronic obstructive pulmonary disease (COPD), may be evaluated 
in the clinical setting with single frequency bioelectrical impedance analysis 
(SF-BIA) and handgrip strength (HGS) test, respectively. In addition to BIA-
derived body composition estimates, phase angle (PhA) is a raw BIA variable, 
considered as a potential marker of muscle quality. The aim of the present study 
was to assess whether PhA is a predictor of HGS and respiratory muscle strength 
in COPD patients, possibly stronger than anthropometric variables and BIA-
derived body composition estimates. 
Two-hundred and thirty-seven COPD patients (161 M, 76 F) underwent 
respiratory, anthropometric, SF-BIA (Human Im-Touch analyser, © DS Medica 
S.r.l., Milan, Italy), HGS and respiratory muscle strength (maximum 
inspiratory/expiratory pressure−MIP/MEP) measurements. FFM was estimated 
using three disease-specific BIA equations. BIA variables and HGS were 
calculated as the mean of dominant and non-dominant body sides. 
Linear correlation analysis showed that in COPD patients the association of 
HGS with PhA (p<0.001) was stronger compared to those with anthropometric 
variables and FFM estimates. In multiple regression analysis, PhA emerged as 
an independent predictor of HGS in males (adjusted R2=0.502; p<0.001) and 
females (adjusted R2=0.426; p<0.001). With respect to respiratory muscle 
strength, a stronger association was also found between MIP and PhA (r=0.456 
in males and r=0.421 in females; p<0.001) and, only in males, between MEP 
and PhA (r=0.450; p<0.001), compared to anthropometrics and BIA-derived 
FFM estimates. 
In conclusion, as a raw variable, phase angle is the best predictor of 
handgrip strength in COPD patients, possibly providing more useful 
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information than BIA-derived FFM for the assessment of muscle quality beyond 
the use of body composition equations. 
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1. Introduction and aims  
Skeletal muscle abnormalities are highly prevalent extra-pulmonary 
consequences in COPD patients (1, 2) in terms of loss of fat free mass (FFM)(3)  
and decreased muscle strength (4). 
A decrease of FFM (atrophy) (2) was observed in 4 to 35% COPD patients 
and may occur independently of preserved or even increased body mass index 
(BMI) (5, 6).  
From a clinical perspective, low FFM, independently of BMI and fat mass, 
may have adverse effects on health status (7), increasing the frequency or 
severity of acute exacerbations of the disease, and being a strong predictor of 
mortality (8, 9).  
Bioelectrical impedance analysis (BIA) provides estimates of FFM by 
means of predictive equations which include BIA variables and frequently other 
variables such as age and weight (in some cases gender) (10). As an alternative, 
the use of raw BIA variables, such as phase angle (PhA) or impedance ratio 
(IR), has gained popularity in the clinical setting, in order to evaluate the 
extracellular/intracellular distribution of water, body cell mass and muscle 
quality (10-16). 
Higher PhA, which is a directly-measured (raw) BIA variable expressed in 
degrees (17), suggests greater cell quantity or better muscle quality, while a 
smaller PhA suggests cellular loss or reduced cellular integrity (18). Preliminary 
data in COPD showed that PhA significantly decreased across COPD stages 
(19). Furthermore, it was found to be negatively correlated with age and 
positively with BMI and FEV1 (% predicted) (12). 
Decreased muscle strength (or weakness) is also common in COPD, 
affecting both lower and upper limb muscles (1), possibly due to a number of 
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specific reasons such as deconditioning, inflammation, malnutrition, oxidative 
stress, hypoxemia, in addition to a loss of muscle mass (2). 
Lower limb muscle strength, which is usually evaluated by measuring 
isometric knee extension strength (i.e. the quadriceps strength), is reduced by 
20 to 30% in COPD patients (2), and is considered to be a strong predictor of 
both exercise capacity and mortality (20). 
Similarly, handgrip strength (HGS), which is related to the strength of 
forearm and hand muscles, was found to be reduced in malnourished/sarcopenic 
COPD patients (21-25), being inversely associated with their quality of life and 
mortality (26, 27).   
Despite the obvious interest in evaluating changes in both body composition 
and skeletal muscle abnormalities − for example, for defining nutritional 
phenotypes(9) − only few studies (28-33) have provided data on  the 
relationship between upper and lower limbs muscle strength and FFM. Patients 
with depleted FFM (measured by BIA) were previously found to have lower 
HGS (29, 30). More specifically, preliminary data evidenced a significant 
correlation between HGS and BIA-derived FFM (31, 32)  Nevertheless, the 
relation between muscle strength and raw BIA variables has so far been poorly 
evaluated in COPD (12, 15).  Furthermore, to the best of our knowledge only 
three papers have focused on the relationship between respiratory muscle 
strength and body composition (34-36), none of which took into consideration 
raw BIA variables. 
With this perspective, the major aim of this study was to assess 
retrospectively the relationship between HGS and raw single frequency BIA in 
COPD patients. We also tested the hypothesis that raw  single frequency BIA 
(SF-BIA) variables are stronger predictors of HGS than anthropometrics and 
body composition BIA estimates (e.g., FFM). The secondary aim was to analyse 
the relationship between maximum inspiratory and expiratory muscle strength 
and SF-BIA variables. 
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2. Methods 
2.1 Subjects 
Patients with COPD, consecutively admitted to the Pulmonary Rehabilitation 
Section of Clinic Center S.p.A (Naples, Italy) from March 2013 to May 2016, 
were assessed for eligibility. Inclusion criteria were age >50 years and a baseline 
post-bronchodilator forced expiratory volume in 1 second (FEV1)⁄forced vital 
capacity (FVC) < 0.7. Exclusion criteria were related to diagnosis of known 
respiratory disorders other than COPD, known history of significant 
inflammatory disease other than COPD and a COPD exacerbation within 4 
weeks of enrolment. The Ethics Committee of the “Federico II” University of 
Naples approved the research protocol and all patients gave informed consent 
to participate in the study. 
2.2 Lung function  
All COPD patients performed a baseline post-bronchodilator spirometry and 
body plethysmography (QBOX® COSMED) according to American Thoracic 
Society (ATS)/European Respiratory Society (ERS) standardization (37). FEV1 
and FVC were assessed in accordance with the latest GOLD guidelines (38).  
Patients were classified into four stages according to the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) criteria.  If FEV1 ≥ 80% of the 
predicted, patients were classified as GOLD stage I (mild), if 50% ≥ FEV1 >80% 
of the predicted, as GOLD stage II (moderate), 30% ≥ FEV1 >50%  of the 
predicted as GOLD stage III (severe), and if <30% of the predicted as  GOLD 
stage IV (very severe).  
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2.3 Body composition 
Body weight and body height were measured to the nearest 0.1 kg and 0.5 cm 
respectively, using a mechanical column scale (SECA 711+220; Hamburg - 
Germany), and BMI was calculated as body weight⁄height.2 Body composition 
was assessed by performing BIA in standardized conditions (i.e. ambient 
temperature between 23 and 25°C,  fast of > 3 h, empty bladder, supine position 
for at least 10 minutes before starting the measurement), using a Human Im-
Touch analyzer (© DS Medica S.r.l., Milan, Italy). In addition, after cleaning 
skin surface, patients were asked to lay with legs and arms slightly abducted at 
30° so there was no contact between the extremities and trunk.  
A standard tetra-polar technique was used, with measuring electrodes 
placed on the anterior surface of the wrist and ankle, and injecting electrodes 
placed on the dorsal surface of the hand and the foot, respectively. Z and phase 
angle were obtained at 50 kHz for both dominant (D) and non-dominant (ND) 
sides with an imperceptible electrical current of 800 mA. In addition, 
bioelectrical impedance index (BI index) was calculated as squared height 
divided by impedance at 50 kHz, representing an established parameter of total 
body water (TBW) (39). Phase angle, expressed as a degree, provides 
information on hydration status, cellular mass and quality (17, 18). FFM and 
FFM index (FFMI kg/m2 = FFM/height2) were estimated from Z at 50 kHz using 
three different BIA equation (40-42). Fat mass (FM) was calculated as total 
body weight minus FFM and FMI (kg/m2) as FM/height2. 
2.4 Muscle strength 
HGS, a surrogate measurement of overall muscle strength (43), was measured 
at baseline with a digital dynamometer (Dynex, MD systems Inc .Ohio USA). 
Three measurements were taken for both body sides (dominant and non 
CHAPTER VI 
155 
 
dominant). Mean value of the two body sides was indicated as whole body HGS 
(or HGS). The maximum values were considered for statistical analysis (44). 
Respiratory muscle strength was measured as maximum inspiratory 
pressures (MIP) and maximum  expiratory pressures (MEP), according to the 
method described by Black and Hyatt (45). Measurements were obtained in the 
sitting position with MicroRPM® (CareFusion, Hoechberg, Germany). 
2.5 Other measurements 
Breathlessness was measured  using the Medical Research Council (MRC) dyspnoea scale 
(46). A composite prognostic index, the BODE index (47), was used as surrogate of global 
disease severity. 
2.6 Statistical analysis 
Whole body data were obtained by calculating the mean of the measurements 
taken for D and ND body sides. Values were reported as mean ± standard 
deviation (SD) unless otherwise specified.  
Pearson correlation coefficient was used to evaluate the association between 
variables, a general linear model was applied for adjusting data for age, weight 
and BMI.  
The McNemar's test was used to compare the prevalence of low muscle mass 
according to the different FFM equations. Statistical analysis was performed 
using SPSS version 20.0 and a p value <0.05 was considered significant in all 
analyses. 
3. Results 
Two hundred and thirty-seven patients (161 males and 76 females) with stable 
COPD were studied. The majority of patients had moderate to severe impaired 
lung function, as 3.4% of patients were classified in GOLD stage I, 30.4% in 
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GOLD stage II, 39.7% in GOLD stage III, and 26.6% in GOLD stage IV. 
Characteristics of the whole group of patients were shown in table 1.  
3.1 SF-BIA data 
As far as raw SF-BIA data are concerned, BI-indexes were significantly lower 
by about 23.3% in females than males (p<0.001), while PhA was higher (by 
6.0%) in males (p=0.034). PhA was inversely correlated (p<0.001) with age, 
both in males (r=−0.281) and females (r=−0.202), and directly correlated with 
height (r=0.188; p=0.017), weight (r=0.317; p<0.001) and BMI (r=0.282; 
p<0.001) only in males. In a multivariate analysis age (p<0.001), BMI (p=0.02) 
and FEV1 measured (p<0.001) emerged as simultaneous significant predictors 
of PhA in males, while height and weight did not (overall adjusted R2=0.220, 
p<0.001). On the contrary, in females, the only significant determinant of PhA 
was FEV1 measured (overall adjusted R2 =0.049, p=0.031). 
A significant decrease of PhA across GOLD stages was reported only in 
males (5.37±0.89 degrees, 5.00±0.92 degrees and 4.82±0.99 degrees in I+II, II 
and IV, respectively; p=0.02). Furthermore an inverse correlation with BODE 
index was also reported, both in males (r=−0.343, p<0.001) and females 
(r=−0.358, p=0.006). 
With regards to body composition, FFM was estimated by using three 
different equations. Whichever predictive equation used, FFM and FFMI were 
clearly significantly higher and percentage of body fat lower in males compared 
to females (table 2).  
In both genders, FFM and FFMI estimates significantly differed depending 
upon the equation used. Mean FFM (and, consequently, FFMI) was the highest 
when the Rutten equation was used and the lowest when the Kyle equation was 
used. 
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3.2 Relationship between muscle strength and body composition 
With respect to simple correlation analysis, the association between HGS and 
demographic and anthropometric parameters was more evident in males than in 
females. In males, HGS (p<0.001) was inversely related to age, and directly to 
height, weight and BMI, while in females a significant relationship emerged 
only for height (p<0.001) and less consistently for age (p=0.07). With respect 
to respiratory muscle strength, a significant relationship emerged in males 
between MIP and weight, BMI, and FEV1 (r=0.424) (similar relationship 
emerged with MEP); while in females a significant relationship was found 
between MIP and weight and FEV1 (r=0.347), MEP and weight and BMI. 
Indeed, FFM tended to be more strictly associated with HGS (r between 0.472 
and 0.480, in males, and between 0.235 and 0.302, in females), than 
demographic and anthropometric variables. The association with HGS was 
clearly weaker (i.e. r below 0.3) for FFMI, independently of the equation used 
(data not shown).  
In addition, our findings showed that BI indexes were positively and more 
strongly correlated with HGS compared to BIA-derived FFM estimates (quite 
more strongly in males than in females) (table 3). Similar data were obtained 
from the two sides separately. Interestingly, the association was even stronger 
for PhA (r=0.584, p<0.005 and r=0.635, p<0.005 in males and female, 
respectively−figure 1).  
Similar results were obtained for respiratory muscle strength. Indeed, PhA 
was more strongly related to MIP and MEP compared to BI index and, more 
interestingly, compared to FFM estimates (table 3), in males. In females, a 
positive and moderate relation emerged only with respect to MIP (but not to 
MEP). 
Multiple regression model was applied in order to identify the best 
predictors of HGS, first considering demographic and anthropometric variables, 
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plus FEV1 as potential determinants. In males, age (p<0.001), height (p<0.001), 
weight (p<0.001), BMI (p<0.001) and FEV1 (p=0.002) entered into the model 
with a coefficient of determination (R2) of 0.333. In females, only height entered 
into the model (age, weight, BMI and FEV1 were excluded) with a R2 of 0.280. 
Similar findings were obtained when D and ND sides were considered 
separately (data not shown).  
When included together in the regression model, age, FFM and FM (FEV1 
was excluded) all emerged as determinants of HGS in all models, except for age 
and FM in females when the Steiner equation was used. Adjusted R2 was 0.397, 
0.388 and 0.412 in males, and 0.221, 0.043 and 0.201 in females for Rutten, 
Steiner and Kyle equation, respectively. 
Finally, age FFM, raw BIA variables and FEV1 were taken into 
consideration. PhA and BI index emerged as predictors of HGS (table 4), 
together with age only in males. The R² of the regression were 0.502 and 0.426 
in males and females, respectively. In practical terms, HGS was almost 3 kg 
higher for each degree of PhA increased in both genders (1 degree roughly 
corresponds to 1 SD). Similar results emerged when dominant and non-
dominant sides were considered separately (data not shown). 
Similarly, a multiple regression analysis was applied in order to identify the 
best predictors of MIP and MEP, with age FFM, raw BIA variables and FEV1 
as independent variables. As shown in table 4, PhA and BI index emerged as 
predictors of both MIP and MEP in males, while in females, only PhA emerged 
as predictor of MIP, (p<0.001 for all analysis), but not of MEP. 
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4. Discussion 
The main finding of the present study is that in COPD patients, raw SF-BIA 
variables (BI index and PhA) are strong predictors of muscle strength, as 
expressed by HGS, and to a more significant extent compared to age, height, 
weight, BMI and body composition estimates derived from  BIA (i.e. FFM) . 
As an additional finding, we have also observed that, in the same way, MIP and 
MEP tended to be more strictly related to raw BIA data than to other potential 
predictors, as above mentioned. 
As recently outlined (9), different metabolic phenotypes may be described 
in COPD patients, by assessing body composition and muscle strength, such as 
muscle wasting, sarcopenia, sarcopenic-obesity and obesity. Actually, loss of 
skeletal muscle mass and weakness are highly prevalent in COPD, being 
associated with decreased physical activity, exercise intolerance, poor quality 
of life, and higher morbidity and mortality (2, 27). 
FFM and, more specifically, skeletal muscle mass, can be assessed in terms 
of quantity and quality (i.e., body cell mass and cellular integrity). With this 
perspective, raw BIA variables (BI index and PhA) are receiving increasing 
attention, beyond using them in body composition equations, as suggested by a 
growing number of authors (10, 14, 18, 48). For instance, phase angle is thought 
to provide direct information on cellular mass and muscle quality (18, 49). 
Very few data have been published on PhA in COPD (12, 15, 19). It was 
previously shown to be higher in males, negatively correlated with age and 
positively with BMI and FEV1 (% predicted) (12). Furthermore, it was shown 
to be significantly decreased across COPD stages possibly because of the 
decreased cell integrity (19). We extended these observations (12, 19) by 
examining determinants of PhA separately in males and females, finding a 
significant decrease of PhA across GOLD stages in males, a direct correlation 
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with FEV1 in both genders, an inverse correlation with age and a direct 
correlation with BMI only in males.  
Furthermore, in a multivariate analysis, PhA, age, FEV1 and BMI emerged 
as significant predictors of PhA in males, and only FEV1 in females. 
In addition, it should be noted that underweight male patients (BMI<21 kg/m2) 
have lower values of PhA compared to those with a higher BMI (4.49±0.98 
degrees vs 5.10±0.90 degrees; p<0.001). No difference was found in 
underweight female patients compared to those with a normal weight. Further 
investigations are needed in the future, in order to better understand whether the 
occurrence of this between-genders difference is real and due to a physiological 
gender dichotomy, and to relate it with nutritional status. 
Loss of skeletal muscle strength is another feature of muscle dysfunction, 
and a major systemic consequence of COPD (2). According to the European 
Working Group on Sarcopenia in Older People (EWGSOP), low skeletal muscle 
strength can be diagnosed by measuring HGS, a good and reliable surrogate for 
more complicated measures of muscle strength, such as isokinetic quadriceps 
muscle strength (50).  
In agreement with previous studies showing reduced HGS in COPD (51), 
low HGS (<30 kg in males and <20 kg in females, according to EWGSOP), has 
been found in 63.4% and 71.1% of our male and female COPD patients, 
respectively. 
Taking into consideration the scarcity of data, the primary aim of the present 
study was to evaluate the relationship of muscle strength (in terms of both HGS 
and respiratory muscle strength) and raw BIA variables, estimates of body 
composition and other potential predictors. 
Indeed, very few studies have provided limited data on the relationship 
between muscle strength and body composition in COPD (none as primary 
endpoint), showing that patients with depleted FFM had lower HGS (29-32). 
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Furthermore, only one paper has already been published on the association 
between quadriceps strength and PhA (12). 
Simple correlation analysis shows that HGS is more strongly related to raw 
BIA data and, in particular, to PhA, compared to anthropometric variables and 
FFM estimates, demonstrating that PhA may represent a novel marker of 
cellular mass and muscle quality. 
In order to identify the best predictor of muscle strength, we have analysed 
several potential determinants of HGS (age, FEV1, BIA-derived FFM estimates, 
BI index and PhA), finding an inverse relation between HGS and age only in 
males, in the way that older male patients are more prone to have lower HGS 
values (−0.27 kg for each year). 
Furthermore, raw BIA variables emerged as significant predictors of HGS, 
while FFM estimates and FEV1 did not. In particular, HGS directly increases by 
0.25 kg for each cm2/ohm of BI index and 2.83 kg for each degree of PhA at 50 
kHz, in males. In females, a similar association was found between HGS and 
PhA, in the way that HGS increases by 3.09 kg for each degree of PhA at 50 
kHz. Nevertheless, differences emerged with respect of the association with BI 
index, between genders.  
Interestingly, when considered simultaneously in the regression model, age, 
FEV1 and BIA-derived FFM estimates were excluded. 
Respiratory muscle strength is another objective functional measure with 
prognostic potential in COPD patients (52). In particular, a single study has 
shown that MIP was associated with PhA in cancer patients (53), while to the 
best of our knowledge no data are available in COPD. Actually, we have found 
a positive association between respiratory muscle strength and raw SF-BIA data 
(PhA and BI index). A possible explanation to this association could be the 
reduced mass of the diaphragm muscle and chest wall or reduced mechanical 
efficiency of the respiratory muscles in COPD patients with poorer body 
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composition (54). The association between respiratory muscle strength and raw 
BIA variables was stronger compared to those with other potential predictors 
(anthropometrics and BIA-derived FFM estimates). Furthermore, PhA emerges 
as an independent predictor of both MIP and MEP in males, and only of MIP in 
females, highlighting that PhA, as raw SF-BIA variable, represents a novel 
marker of cellular function and muscle quality (also in terms of muscle 
strength).  
Some limitations of the study must be acknowledged. Firstly, this is a single 
centre study, which, does however, include COPD patients referred for a 
pulmonary rehabilitation program, from several hospitals and chest physicians 
in Campania (number of residents = 5,850,850), South Italy. 
Secondly, although BIA is a reliable method for measuring FFM and FFMI 
in population studies (48), no reference technique  for body composition (e.g. 
dual-energy X-ray absorptiometry) was available. However, given the 
advantages of BIA, it has great potential for measuring body composition in 
large populations, being less expensive, and more easily accessible than other 
methods in clinical settings. On the other hands, three disease specific BIA 
equations were considered in order to obtain estimates of FFM. Furthermore, it 
should be noted that muscle strength as well as body composition measurements 
have been taken for both body sides, separately, in clinically stable patients. All 
measurements are highly repeatable and reproducible. To the best of author’s 
knowledge, this is the first study, which takes into consideration raw SF-BIA 
data as independent predictors of handgrip strength. 
In conclusion, the present study demonstrates that PhA, as raw BIA 
variable, is an independent predictor of muscle strength, more strongly 
associated to HGS and respiratory muscle strength, compared to and BIA-
derived FFM estimates and, even more to anthropometric parameters, such as 
height, weight and BMI.  The results of this study suggest that the assessment 
of raw BIA variables may have a role in the overall nutritional assessment in 
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COPD. Nevertheless, longitudinal studies are needed to examine whether these 
variables can predict risk of functional decline in these patients. 
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5. Tables and figures  
Table 1. Demographic parameters and raw BIA variables by genders in stable 
COPD patients. 
  
 
Males 
(n=161) 
Females 
(n=76) 
P 
Age (years) 70.4±7.5 68.7±7.8 NS 
Height (cm) 165.2±7.0 152.7±6.3 <0.001 
Weight (kg) 69.9±16.8 64.7±13.7 0.021 
BMI (kg/m²) 25.5±5.5 27.8±5.8 0.004 
FEV1 (% pred.) 41.1±18.2 49.8±20.3 0.001 
FEV1/FVC 54.9±8.4 58.2±7.7 0.005 
Impedance (Ohm) 546±103 600±82 <0.001 
Bioimpedance index 
(cm2/Ohm) 
51.6±9.8 39.6±6.3 <0.001 
Phase angle (degrees) 5.1±1.0 4.8±0.9 0.034 
HGS (kg) 27.8±7.1 18.4±4.6 <0.001 
MIP (mmH20) 56.4±21.0 47.6±18.1 0.002 
MEP (mmH20) 79.8±26.7 71.9±21.3 0.029 
Note: Data are presented as mean ± standard deviation. Bioimpedance index, phase angle and HGS 
expressed as mean of the two body sides. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced 
vital capacity; HGS, handgrip strength, MIP, maximum inspiratory pressure; MEP, maximum 
expiratory pressure. 
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Table 2. BIA-derived body composition, as estimated with different equations, 
in clinically stable COPD patients. 
 
Abbreviations: FFM,fat-free mass; FFMI, fat-free mass index; ASMM, appendicular skeletal muscle 
mass, ASMMI, appendicular skeletal muscle mass index. 
 
  
 
Males 
(n=161) 
Females 
(n=76) 
P 
FFM Rutten (kg) 50.4±7.2ab 38.4±5.1b <0.001 
FFM Steiner (kg) 47.3±7.7ac 38.3±4.9c <0.001 
FFM Kyle (kg) 46.1±6.3bc 36.1±4.7bc <0.001 
    
FFMI Rutten (kg/m2) 18.5±2.1ab 16.5±1.9b <0.001 
FFMI Steiner (kg/m2) 17.3±2.5ac 16.5±2.0c <0.010 
FFMI Kyle (kg/m2) 16.9±1.9bc 15.5±1.8bc <0.001 
    
Body fat Rutten (%) 26.0±8.7ab 39.5±6.5b <0.001 
Body fat Steiner (%) 30.9±7.4ac 39.6±7.2c <0.001 
Body fat Kyle (%) 32.3±8.2bc 43.1±6.4bc <0.001 
Note: Data are presented as mean ± standard deviation.  
P value < 0.05 for significant differences.  
a = p<0.001 between Rutten and Steiner equation 
b = p<0.001 between Rutten and Kyle equation 
c = p<0.001 between Steiner and Kyle equation 
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Table 3. Correlation between body composition and muscle strength in 
clinically stable COPD patients (161 males and 76 females). 
 
Males  Females 
 HGS MIP MEP 
 
HGS MIP MEP 
Age −0.419** −0.056 −0.076 
 
−0.209 −0.176 −0.085 
Height 0.385** 0.073 0.097 
 
0.538** 0.086 0.156 
Weight  0.373** 0.342** 0.307** 
 
0.113 0.245* 0.443** 
BMI 0.255** 0.358** 0.300** 
 
−0.069 0.223 0.395* 
FFM Rutten 0.472** 0.385** 0.342** 
 
0.301** 0.178 0.320* 
FFM Steiner 0.472** 0.423** 0.366** 
 
0.235** 0.173 0.299* 
FFM Kyle 0.480** 0.410** 0.353** 
 
0.302** 0.193 0.317* 
BI index 0.505** 0.447** 0.378** 
 
0.291** 0.182 0.276* 
PhA   0.584**   0.456**  0.450** 
 
0.635** 0.421** 0.127 
Note: Data are presented as coefficients correlation (r). Bioimpedance index, phase angle and HGS 
expressed as mean of the two body sides. 
*p<0.05; **p<0.005 
Abbreviations: BMI, body mass index; FFM, fat-free mass; BI index, bioelectrical impedance index; PhA, 
phase angle; HGS, handgrip strength; MIP, maximum inspiratory pressure; MEP, maximum expiratory 
pressure. 
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Table 4. Multivariate stepwise regression with HGS, MIP and MEP as 
dependent variables for male (M) and female (F) patients, separately. 
 
 
Males 
 
 
 
      
        
HGS 
 
 
= 19.6 
(5.2) 
+ 0.25 × BI-index 
  (0.04)  
+ 2.83 × PhA 
  (0.47) 
− 0.27 × age   
  (0.06) 
R²=0.502 SEE=5.02 
MIP = −16.9 + 0.69 × BI-index + 7.46 × PhA NS R²=0.292 SEE=17.02 
 
 
 (9.2)   (0.16)   (1.59    
MEP = −5.8 + 0.68 × BI-index + 10.07 × PhA NS R²=0.248 SEE=23.16 
  (12.1)   (0.20)   (2.09)    
        
Females 
 
       
        
HGS 
 
 
= − 1.9 
(0.5) 
+ 0.14 ×  BI-index  
  (0.06) 
+ 3.09 × PhA 
  (0.45) 
NS R²=0.426 SEE=3.37 
MIP = 5.3 NS + 8.83 × PhA NS R²=0.165 SEE=16.51 
  (11.1)    (2.28)    
        
MEP = 4.0 + 0.92×  BI-index NS NS R²=0.167 SEE=19.4 
  (17.7) 
 
  (0.36)     
Note: HGS as a mean of the two body sides. Standard errors of the regression coefficients in 
brackets. 
Dependent variables: Age, FFM, BI index, PhA, FEV1. 
FFM and FEV1 were excluded from all models 
Abbreviations: BI index, bioelectrical impedance index; PhA, phase angle; HGS, handgrip strength; 
MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure; SEE, standard error of 
estimate. 
 
CHAPTER VI 
168 
 
Figure 1. Correlation plot between PhA at 50 kHz and HGS in males (r=0.584) and females 
(r=0.635), separately (p<0.005). 
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Abstract 
Visceral adipose tissue (VAT) was shown to be increased in patients with 
chronic obstructive pulmonary disease (COPD) compared to control subjects 
with comparable body mass index (BMI). The aims of the present study were 
to determine the relation of VAT by dual-energy x-ray absorptiometry (DEXA) 
in patients with COPD by disease severity, BMI, other indices of body 
composition and static lung volumes. 
294 COPD patients admitted for rehabilitation were studied. Lung function, 
static lung volumes and body composition (i.e. BMI, waist circumference, fat-
free mass, fat mass and fat distribution between android and gynoid fat mass) 
were assessed before entering pulmonary rehabilitation. VAT was estimated 
within the android region by using DEXA. Patients were stratified for gender, 
BMI (cutoff of 25 kg/m ) and GOLD stage. To assess the impact of VAT on 
lung volumes, patients were also stratified for VAT less and above 50th 
percentile. 
Both male and female patients with more severe airflow limitation had 
significantly lower VAT values, but these differences disappeared after 
stratification for BMI. VAT was significantly and strongly correlated with other 
body composition parameters (all p < 0.001). Patients with moderate to severe 
airflow limitation and lower VAT had increased static lung hyperinflation and 
lower diffusing capacity for carbon monoxide. Nevertheless, multivariate 
stepwise regression models including for BMI, age, gender and forced 
expiratory volume in 1 s (FEV ) as confounders did not confirm an independent 
role for VAT on static lung hyperinflation and diffusion capacity.  
In conclusion, after stratification for BMI, VAT is comparable in moderate 
to very severe COPD patients. Furthermore, BMI and demographics, but not 
VAT, were independent predictors of static lung hyperinflation and diffusing 
capacity in COPD.  
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1. Introduction and aims 
Although defined by the presence of persistent airflow limitation (1), alterations 
in body weight and body composition contribute to disease severity in patients 
with chronic obstructive pulmonary disease (COPD). Indeed, low body mass 
index (BMI) (<21 kg/m2) is related to poor exercise tolerance (2), low fat-free 
mass (FFM) (3) and co-morbid osteoporosis (4). Furthermore, it is incorporated 
in the prognostic assessment of COPD (5). Otherwise, high BMI (≥30 kg/m2) is 
related to increased dyspnoea (6), reduced weight-bearing exercise performance 
(7) and systemic inflammation in COPD (3). At the same time, reductions in 
lung volumes have been consistently reported in obese COPD patients (8). 
In addition to the discriminating role of BMI in the clinical phenotyping of 
COPD patients, alterations in body composition, i.e. the distribution between 
FFM and fat mass (FM), are common and have additional impact on the burden 
of disease. In more detail, visceral adipose tissue (VAT) is receiving increasing 
attention in COPD, since it was shown that elderly subjects with obstructive 
lung disease have increased visceral adipose area in comparison with control 
subjects with comparable BMI (9). Also, there is increasing evidence for a role 
of VAT in the pathophysiology of systemic inflammation (10) and 
cardiovascular morbidity in COPD (10, 11).  
Typically, VAT is assessed by computer tomography (CT) or magnetic 
resonance imaging (MRI), but these measurements are expensive, time-
consuming and not widely available. Alternatively, dual-energy x-ray 
absorptiometry (DEXA) is a commonly used device with lower radiation dose, 
alternative to estimate body composition in COPD and was recently introduced 
as a validated method to quantify VAT (12, 13). However, no clinical studies 
investigating VAT with DEXA was carried out yet in COPD patients. Thus, 
associations between VAT assessed by this method and other traditional 
markers of body composition in COPD was still unknown. Also, the impact of 
VAT per se on lung volumes was not previously studied in COPD.  
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Therefore, the aims of the present study were: 1) to quantify the amount of 
VAT measured by DEXA in patients with COPD in relation to disease severity 
and BMI; 2) to explore the relationships between VAT and other indices of body 
composition and 3) to study the impact of VAT on static lung volumes. In the 
present study, we hypothesized that VAT does significantly and negatively 
influence static lung volumes and hyperinflation in patients with COPD. 
2. Methods 
2.1 Subjects 
Data were abstracted from the Integrated Knowledge System based on 
BioXM™ (Biomax Informatics AG, Munich, Germany) of 294 patients with a 
primary diagnosis of COPD (post-bronchodilator forced expiratory volume in 1 
s (FEV1)/forced vital capacity (FVC) ratio of ⩽0.70 and post-bronchodilator 
FEV1 <80% predicted) who were evaluated during the initial assessment of a 
comprehensive pulmonary rehabilitation (PR) program at CIRO Horn (The 
Netherlands) between August 2014 and May 2015 (14). Exclusion criteria were: 
a history of asthma, a1-antitrypsin deficiency, lung cancer, any previous lung 
surgery, instable inflammatory or endocrine diseases, acute myocardial 
infarction within the last 6 months, any known bone disease other than 
osteoporosis, treated malignant disease within the last 5 years and an 
exacerbation of COPD within the last 4 weeks. Ethical approval was not 
indicated because all of the tests were done as part of the routine initial 
assessment (14), and analyzed retrospectively. The Board of Directors of CIRO 
approved the use of de-identified patients’ records. 
2.2 Lung function measurement 
As part of the routine 3-day initial assessment of integrated health status, all 
patients performed post-bronchodilator spirometry (Masterlab®; Jaeger, 
Würzburg, Germany). FEV1 and FVC were assessed in accordance with the 
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latest GOLD guidelines (1). Inspiratory vital capacity (IVC) was assessed too. 
Plethysmographic lung volumes, such as Total Lung Capacity (TLC), Intra 
Thoracic Gas Volume (ITGV), Expiratory Reserve Volume (ERV) and 
Residual Volume (RV) were assessed. Inspiratory Capacity(IC)/TLC ratio (15) 
was calculated by dividing TLC−ITGV for TLC, and was used as a marker for 
hyperinflation (defined as an abnormal increase in the volume of air remaining 
in the lungs at the end of spontaneous expiration (16)). Diffusing capacity of the 
lung for carbon monoxide (DLCO) was measured using the single-breath 
method. All obtained values are expressed as percentages of the predicted value, 
by comparison with age and sex-specific reference values (17). 
2.3 Body composition 
Body height was measured to the nearest 0.5 cm with a wall-mounted 
stadiometer. Body weight was assessed to the nearest 0.1 kg using a weighing 
scale, and BMI was calculated as weight/height2. A total body scan was 
performed by DEXA using a Lunar Prodigy® system (GE Healthcare - 
enCORE v14, Madison, WI, USA). Subjects lay supine on the DEXA table with 
arms adequately separated from the trunk and were instructed to remain still 
throughout the scanning procedure. After analysis of the whole body scan, a 
quadrilateral box was manually drawn around the L1–L4 region of interest 
(abdomen) bounded inferiorly by the horizontal line identifying L4/L5 vertebral 
space and superiorly by the horizontal line identifying the T12/L1 vertebral 
space. Scans were displayed with an adjustment of the gray scale, so that all of 
the soft tissue in the designated area was included. From the total body scan, 
body composition was assessed: bone mineral content (BMC), lean mass (LM), 
FFM (LM plus BMC). FFMI was calculated by dividing FFM by height2, and 
FM by subtracting FFM from total weight. The base of the android region 
(figure 1A - shown in blue) sits immediately above the pelvis and is in height 
equal to 20% of the distance from the pelvis to the chin. The android and gynoid 
(figure 1A - shown in red) regions are separated by a distance equal to 1.5 times 
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the height of the android region, while the height of the gynoid region is double 
that of the android one. VAT was estimated within the android region (12) 
(figure 1B number 1).  
2.4 Statistical Analysis 
Values are reported as means ± SD with the exception of continuous variables, 
presented as median and interquartile range (IQR).  In order to quantify the 
amount of VAT in relation to disease severity, patients were stratified for 
gender, BMI (cut-off of 25 kg/m2) and GOLD stages (I+II, III, IV). Since the 
proportion of patients with mild airflow limitation referred for PR is limited 
(18), these patients were grouped with those with moderate airflow limitation. 
Furthermore, in order to study the impact of VAT on lung volumes, both men 
and women were divided in two subgroups according to VAT 50th percentile 
(2183.0 g for men and 912.5 g for women). 
Statistical analysis was performed using SPSS version 20.0. Comparisons 
across GOLD stages were performed using ANOVA with post-hoc Tukey-
Kramer tests for multiple comparisons. Subsequently, multivariate stepwise 
linear regression analysis was performed to investigate a relationship between 
VAT and selected indices of lung hyperinflation. A p value <0.05 was 
considered significant in all analyses. 
3. Results 
3.1 Subjects characteristics 
Patients were characterized by moderate to very severe airflow obstruction 
(GOLD I/II, 44.9%; GOLD III, 38.1%; GOLD IV, 17.0%). 154 (52.4%) were 
men (median age 67 years, IQR 13 years; median BMI 26.9 kg/m2, IQR 8.6 
kg/m2) and 140 (47.6%) were women (median age 61 years, IQR 13 years; 
median BMI 25.3 kg/m2, IQR 8,1 kg/m2). The median number of pack years 
smoked was 40 (IQR 24) 30.3% of patients were current smokers and 63.6% of 
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patients were former smokers. 25.5% of patients used long-term oxygen 
therapy. 
3.2 VAT across GOLD stages  
The amount of VAT separated for men and women is shown in figure 2A. In 
each GOLD subgroup VAT was greater in men than in women (in all GOLD 
stages: p< 0.001). Furthermore, patients with more severe airflow obstruction 
had significantly lower values of VAT, both in men (GOLD I/II: 2501.1 g ± 
1141.7 g; GOLD III: 2246.4 g ± 1488.5 g; GOLD IV: 1697.2 g ± 1350.1 g, p 
=0.031) and women (GOLD I/II: 1259.7 g ± 938.0 g; GOLD III: 1160.0 ± 929.8 
g, GOLD IV: 653.0 ± 442.8 g, p =0.015). Figure 2B shows the amount of VAT 
in the three different GOLD subgroups after stratification for BMI: as it could 
be expected, patients with a BMI≥25 kg/m2, had consistently higher values of 
VAT, compared with those with a BMI<25 kg/m2 (p<0.001), both in men and 
women. After stratification for gender and BMI, differences in VAT across the 
three GOLD subgroups disappeared (figure 2B).  
3.3 Relationships of VAT with other indices of total and central adiposity  
The amount of VAT was significantly and strongly correlated with BMI, waist 
circumference, FM, FMI, android fat mass and gynoid fat mass (figures 3 A-F).  
The strength of correlations was higher in male than in female patients. Android 
fat mass was the most strongly correlated with VAT (r2=0.919 in men; r2=0.857 
in women), followed by waist circumference (r2=0.831 in men; r2=0.757 in 
women), FM (r2=0.858 in men; r2=0.694 in women), FMI (r2=0.894 in men; 
r2=0.653 in women), BMI (r2=0.826 in men; r2=0.641 in women) and gynoid fat 
(r2=0.746 in men; r2=0.467 in women). 
3.4 Impact of VAT on lung volumes 
Besides disease severity, patients were stratified for VAT less and above the 
50th percentile. Patients with moderate to severe airflow limitation and lower 
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VAT levels had increased ITGV and ERV and reduced IC/TLC (table 1) 
compared to those with higher VAT levels. There was no significant difference 
for FEV1 (% pred), FEV1/FVC (%) or IVC (% pred), or for lung volumes in 
GOLD IV patients. 
The same trend was observed in both genders, although it was less 
pronounced in female than in male patients (data not shown). DLCO was 
significantly increased in patients with greater VAT in all GOLD categories 
(p=0.002 in GOLD I+II; p=0.003 in GOLD III; p=0.015 in GOLD IV). The 
same finding was true when considering male and female patients separately. 
3.5 Determinants of hyperinflation 
In order to investigate whether VAT itself is a predictor of lung hyperinflation, 
independently from BMI, age, gender and FEV1 (L), stepwise regression was 
performed and results are shown in table 2A.  Considering IC/TLC (%) as 
dependent variable (and FEV1 as the best predictor), the r2 of the regression 
model was 0.701. Only FEV1 (L), BMI, age and gender are included in the final 
equation and the multiple regression was significant (p<0.001). VAT was 
excluded from the model.  
Similar results were obtained when choosing ITGV (L) as dependent 
variable (table 2B). Only BMI, gender, FEV1 (L) and age were significant 
determinants, the r2 was 0.465 and the regression was significant (p<0.001). 
VAT was again excluded from the model. 
Concerning diffusing capacity, stepwise regression results showed that 
FEV1 (L), age, gender and BMI were significant determinants of DLCO (L) in 
the way that younger male patients and patients with higher BMI and higher 
FEV1 (L),  have also higher DLCO values (table 2C). Nevertheless, VAT was 
again excluded from the model. The r2 of the regression model was high (0.532), 
and the regression was significant (p<0.001). 
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4. Discussion 
The present study reported several novelties regarding the research concerning 
the involvement of the adipose tissue in the pathology of COPD. First, it showed 
that VAT is comparable across GOLD stages for airflow limitation if BMI is 
taken into account. Second, traditional markers of total and central adiposity 
correlated very well with VAT assessed by DEXA. Third, VAT is not an 
independent predictor of static lung hyperinflation in COPD, while 
demographics and BMI are.  
4.1 VAT in COPD 
Furutate et al. (19) investigated VAT in patients with COPD using CT. They 
observed that VAT was higher in COPD compared to controls with comparable 
BMI, and that VAT tended to increase with COPD progression, although not all 
differences  were  statistically  significant. In addition, the authors found that, 
in patients with severe emphysema, VAT was retained despite the absence of 
obesity. In the same study, BMI, waist circumference, FFMI, FMI and SAT 
were shown to decrease with increasing emphysematous severity. Besides the 
fact that we did not relate VAT to emphysema severity, the differences in 
ethnicity (Furutate included a Japanese sample, the present study population 
were all caucasians) between studies makes comparison  difficult, but our 
results indicates that VAT is comparable across GOLD stages, after 
stratification for BMI.  
4.2 Assessment of VAT in COPD 
Several methods can be used for measuring VAT. The most commonly used 
imaging technique is abdominal CT, one of the current gold standards for 
quantifying VAT (20-24). However, because of the radiation dose involved, the 
high costs and the heavily utilized clinical equipment requirement, CT is not 
optimal as screening method for VAT. MRI has also been used for VAT 
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measurement (25, 26). It avoids the radiation dose involved with CT 
measurements but still requires an expensive and time-consuming procedure as 
well as heavily utilized clinical equipment. DEXA is another suitable clinical 
reference method for the assessment of body composition. It measures the 
differential attenuation of two different energy level x-rays as they pass through 
the body and subdivides soft tissue into bone, lean and fat compartments. New 
software was recently proposed to quantify VAT in the android region by 
DEXA (12, 13), with several advantage relative to CT and MRI, such as lower 
costs, lower x-ray exposure and short-scanning time (27-30). 
4.3 Correlates of VAT 
To the best of author’s knowledge, no data have been previously published with 
respect of the relationships between VAT measured by DEXA and other indices 
of body composition in COPD patients. In the present study we find a strong 
and significant correlation of VAT with BMI, waist circumference, FM, FMI as 
well as android and gynoid fat mass, in both genders but more strongly in males 
(likely due to their higher amount of VAT compared with females). As reported 
by Kaul et al., DEXA is a valid tool for quantification of VAT and other adipose 
tissue regions in the clinical setting (12), but more studies are needed in COPD 
in order to validate this method against CT, which is one of the current gold 
standards for quantifying VAT. 
4.4 Hyperinflation in COPD 
To the best of the authors’ knowledge, this study is the first that carefully 
evaluated VAT by DEXA in relation to static lung volumes in a large group of 
patients with moderate to very severe COPD. O’Donnell et al.(31) examined the 
relationship between increasing BMI and plethysmographic lung volumes in a 
population with airflow obstruction. It was shown that lung hyperinflation 
decreased exponentially with increasing BMI. However, the potential impact of 
fat distribution on lung volumes was not investigated. In the present study, 
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patients with greater VAT seemed to have lower ITGV, ERV, RV and higher 
IC/TLC and DLCO without a difference in FEV1, FEV/FVC or IVC in most 
GOLD stages (and most pronounced in early GOLD stage). This finding 
appears to confirm that the major effect of obesity is on lung volumes, with no 
direct effect on airway obstruction (32). The results of the multiple stepwise 
regression analysis confirmed a predicted role of FEV1, BMI, gender and age 
on lung hyperinflation but no independent role of VAT for any of the lung 
volume parameters. This finding is somewhat surprising, since VAT is located 
in the abdominal region below the respiratory compartment. Future studies have 
to seek out what parameters of obesity are related to lung hyperinflation. 
Probably SAT in the abdominal and thoracic region could be worth considering. 
In health, increasing BMI is known to be associated with increasing 
diffusing capacity, possibly reflecting the increased pulmonary blood volume 
in obesity (33, 34). In the current study, a relationship was confirmed between 
increasing BMI and DLCO in COPD patients. Nevertheless, no significant 
predictive role of VAT on DLCO was found. 
 4.5 Strength and limitations of the study 
the major strength of this study was that it is the first study, which used DEXA 
in order to measure VAT in COPD patients. Additionally, a large population 
with moderate to very severe disease and careful clinical characterization was 
enrolled in the study. Nevertheless, various limitations of the study have to be 
considered. Firstly, there was no age-matched healthy control group included in 
the present study. Previous studies however already suggested that COPD 
patients have increased VAT by CT scan compared to matched controls. 
Secondly, no gold standard reference method (such as CT) was available and 
future studies need to validate the DEXA device for VAT. As mentioned in the 
introduction however, this was not the aim of the present study.  
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5. Conclusions 
DEXA provides lots of useful information in clinical practice. Not only is it the 
gold standard method for evaluating bone mineral density and discriminate 
patients with and without osteoporosis, but it is also a useful method for the 
assessment of other clinically relevant body composition parameters, among 
which VAT.  
In conclusion, after stratification for BMI, VAT is comparable across 
GOLD stages in moderate to very severe COPD patients. VAT measured by 
DEXA is strongly correlated to other traditional and most commonly used body 
composition parameters, such as BMI, waist circumference as well as android 
and gynoid fat mass. BMI and demographics, but not VAT, were independent 
predictors of static lung hyperinflation and diffusing capacity in COPD.  
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6. Tables and figures  
Table 1. General and clinical parameters in 294 COPD patients stratified for 
GOLD stages and divided in two groups, based on VAT 50th percentile (2183 g 
for men; 912.5 g for women). 
Table 2A. Multivariate stepwise regression with IC/TLC (%) as dependent 
variable 
 
 
 
 
 
 
 
 
 
 
 
Model Standardized 
Coefficients 
               p 
 
 
(Constant)  <0.001 
FEV1 (L) 0.710 <0.001 
BMI 0.289 <0.001 
Age -0.091 <0.05 
Gender* -0.092 <0.001 
Note: Independent variables: VAT, BMI, age, gender and FEV1. Adjusted R2 = 0.697. VAT 
was excluded from the model. *gender=0 for women; =1 for men. 
Abbreviations: IC/TLC, inspiratory capacity/total lung capacity; FEV1, forced expiratory 
volume in 1second; BMI, body mass index; VAT, visceral adipose tissue. 
CHAPTER VII 
190 
 
Table 2B. Multivariate stepwise regression with ITGV (L) as dependent 
variable 
 
  
 
 
  
Model Standardized 
Coefficients 
p 
 
 
(Constant)  <0.001 
FEV1 (L) 0.428  
Age -0.232 <0.001 
Gender* 0.239 <0.001 
BMI 0.302 <0.001 
Note: Independent variables: VAT, BMI, age, gender and FEV1. Adjusted R2 = 0.525. VAT was 
excluded from the model. *gender=0 for women; =1 for men. 
Abbreviations: ITGV, intra-thoracic gas volume; FEV1, forced expiratory volume in 1second; BMI, 
body mass index; VAT, visceral adipose tissue. 
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Table 2C. Multivariate stepwise regression with DLCO (L) as dependent 
variable 
Model Standardized 
Coefficients 
p 
 
 
 (Constant)  <0.001 
BMI -0.385 <0.001 
 Gender* 0.505 <0.001 
FEV1 (L) -0.391 <0.001 
Age -0.133 <0.005 
Note: Independent variables: VAT, BMI, age, gender and FEV1. Adjusted R2 = 0.458. VAT was 
excluded from the model. *gender=0 for women; =1 for men. 
Abbreviations: DLCO, diffusing capacity of the lung for carbon monoxide;  FEV1, forced expiratory 
volume in 1second; BMI, body mass index; VAT, visceral adipose tissue. 
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Figure 1A. A model of total body DEXA scan. The android region is 
highlighted in blue and the gynoid region is highlighted in red (refer to text for 
further explanations). 
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Figure 1B. Representation of visceral adipose tissue (VAT) and subcutaneous 
adipose tissue (SAT) within the android region 
 
 
 
 
Note: VAT is shown in figure as the sum of 1) omental adipose tissue, 2) mesenteric adipose 
tissue and 3) retroperitoneal adipose tissue. 4) Deep subcutaneous adipose tissue and 5) 
superficial subcutaneous adipose tissue are part of the SAT. 
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COPD is a complex syndrome. Besides the assessment of pulmonary 
function and respiratory symptoms, several extra-pulmonary manifestations and 
comorbidities need to be considered in the individualised management of 
patients. In this perspective, this thesis provides a detailed overview of the 
assessment of nutritional status and body composition in COPD patients, 
especially in relation with respiratory function and muscle strength. 
More specifically, the first study presented in this thesis shows that 
bioelectrical impedance analysis (BIA) has been widely used in COPD, for the 
assessment of body composition. However, no guidelines have so far specified 
how this technique could be applied in order to stratify COPD patients into 
nutritional phenotypes such as malnutrition and sarcopenia.  
Given the lack of information on the prevalence of malnutrition (as defined 
by the European Society of Parenteral and Enteral Nutrition, ESPEN) and 
sarcopenia (according to the European Working Group on Sarcopenia in Older 
People, EWGSOP) the second study of the present thesis focused on the 
assessment of these two conditions, highlighting their association with patients’ 
clinical characteristics. Furthermore, the results of the present study show that 
sarcopenia is more prevalent in malnourished patients compared to non-
malnourished and, within the group of malnourished patients, in those with 
inflammation (cachectic).  
In the third study of the present thesis, multifrequency BIA (MF-BIA) has 
emerged as a useful bedside approach, independently of body composition 
estimates (i.e. fat-free mass), for identifying patients with poor nutritional 
status. More specifically, this study pointed out that raw MF-BIA variables are 
altered in COPD patients compared to healthy controls and correlate well with 
respiratory and muscle function.  
Actually, as resulted from the fourth study presented, raw BIA variables are 
strong predictors of muscle strength, both in terms of peripheral and respiratory 
muscle strength, and to a more significant extent compared to general 
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anthropometric parameters and body composition estimates derived from BIA 
(i.e. FFM). The assessment of raw BIA variables may have a role in the overall 
nutritional assessment in COPD. 
Finally, the fifth study of the present thesis aimed to investigate the 
association of abdominal visceral adipose tissue (VAT) − measured by dual-
energy X-ray absorptiometry (DEXA) − with disease severity and lung 
hyperinflation, finding out no differences in moderate to very severe COPD 
patients, after stratification for BMI.  
Concluding, BIA represents a valuable method to estimate body 
composition in the clinical setting. Theoretically, more accurate methods exist 
to assess muscle mass, e.g. computed tomography, magnetic resonance imaging 
or DEXA, but are expensive, and often hardly accessible in some health settings.  
Several applications of BIA may be encouraged. One is to apply BIA data 
to a validated equation for predicting FFM or appendicular skeletal muscle mass 
(ASM) and then to normalize them to height in order to create standardized 
measures that might be used to diagnose malnutrition or sarcopenia. As an 
alternative, our findings add to evidence regarding clinical applications of BIA 
beyond use in body composition equations. As direct measures, raw BIA data 
(e.g. impedance ratio and phase angle) provides additional information on 
cellular mass and muscle quality, independently of whole-body 
volumes/masses. 
Although future research is needed in order to identify optimal preventive 
and personalized treatment strategies, the results of the five studies of the 
present thesis confirm the need for prevention strategies and suggest possible 
tools for the implementation of effective approaches targeting specific 
populations. 
 
